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NAD(P)H:quinone oxidoreductase (NQO1)-directed lavendamycin antitumor agents:
Structure-based design, molecular modeling and structure-activity studies
Chairperson: Howard D. Beall
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron reductase that catalyzes
an NAD(P)H-dependent activation of many quinone-based antitumor agents. NQO1,
expressed at high levels in many human solid tumors, can be used as a target for enzymedirected bioreductive antitumor drug development. We hypothesized that
lavendamycins, quinolinedione antitumor antibiotics, can be activated by NQO1 in
cancer cells that overexpress NQO1 to exhibit selective toxicity toward those cells. The
effects of functional group changes on the metabolism of lavendamycins by recombinant
human NQO1 were studied using a spectrophotometric assay. These structure-activity
relationship (SAR) studies determined key structural features that were required for
lavendamycin substrate specificity. Cytotoxicity toward human colon adenocarcinoma
NQO1-deficient (BE) and NQO1-rich (BE-NQ) cells was also determined using
colorimetric and clonogenic assays. The best lavendamycin substrates for NQO1 were
also the most selectively toxic to the BE-NQ cells compared to BE cells. To facilitate
structure-based design of more optimal lavendamycin substrates and NQO1-directed
lavendamycin antitumor agent development, we developed a 1H69 crystal structurebased in silico model of the NQO1 active site and performed lavendamycin-docking
studies. The docking was performed using the FlexX module of SYBYL software.
Lavendamycin analogues were designed as NQO1 substrates utilizing our SAR and
docking data as structure-based design criteria. Docking and biological studies on the
analogues were performed and were consistent suggesting the in silico model of the
enzyme possessed practical predictive power. Our results also suggested practicality of
the design criteria resulting in the discovery of good NQO1 substrates with selective
toxicity toward BE-NQ cells. The mechanisms of NQO1-mediated selective cytotoxicity
of good lavendamycin substrates in BE and BE-NQ cells were also investigated including
induction of oxidative stress and apoptosis. Biomarkers of oxidative stress including
formation of 8-hydroxy-2'-deoxyguanosine (8-oxo-2dG), an indicator of oxidative DNA
damage, and depletion of reduced glutathione (GSH) were examined using an HPLCbased method and a colorimetric assay, respectively. Induction of apoptosis was
examined using a colorimetric assay. Our results revealed that oxidative stress and
subsequent apoptosis induction by a good lavendamycin substrate was NQO1 dependent
and that the poor substrate for NQO1 caused neither oxidative stress nor apoptosis.
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Chapter 1
Introduction: NAD(P)H:Quinone Oxidoreductase 1 (NQO1)-directed
Lavendamycin Antitumor Agents
1.1

Enzyme-directed Bioreductive Drug Development
The goal of current cancer therapy and antitumor drug development is to design

cytotoxic drugs that selectively interact with molecular targets ideally unique to tumor
cells with minimal toxicity to normal cells.1-5 This approach, selective anticancer
therapy, aims to design drugs that employ the feasible biochemical and physiological
differences between tumor and uninvolved tissues.4 One approach to achieve selective
toxicity is through bioreductive activation and identifying reductase enzymes that are
overexpressed in tumor cells in comparison to normal counterparts.1,3-5 Workman and
Walton presented the concept of enzyme-directed bioreductive drug development for the
first time at an international symposium in Italy in 1989.5,6 They published their report
on the proposed concept in the conference proceedings in the following year.5,6 In the
enzyme-directed approach, tumor selectivity utilizes the presence of specific reductase
enzymes in high enough levels in tumors to reductively bioactivate chemical agents that
are substrates for the reductases.1,3-7 Potential substrates known as bioreductive
anticancer agents can then undergo reductive activation to selectively produce highly
cytotoxic species in the corresponding tumors.1,3,6-8
In the conference proceedings and 1994 review paper, Workman et al. defined the
major elements of this approach in detail.5,6 Enzyme-directed bioreductive drug therapy
can take advantage of medicinal chemistry as a proper tool to design improved substrates
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for the related enzymes to maximize metabolic reduction of the substrates and subsequent
antitumor response.1,4-6 Another cornerstone of this approach is to determine appropriate
enzymological features of patient tumors (enzyme profiling of tumors).1,4-6 This will
determine presence of elevated levels of reductases in the corresponding tumors and
select patients with the desired enzymatic profile who will most likely respond to
bioreductive anticancer agents.1,4,5 Appropriate design and conduct of clinical trials in
the enzyme-directed approach will be required to correctly assess the efficacy of
bioreductive agents and achieve clinical efficacy.4,5
It has been suggested that NAD(P)H:quinone oxidoreductase 1 (NQO1) is one
important candidate for the enzyme-directed bioreductive drug discovery approach due to
its unique features.1,4,6,8 Elevated NQO1 activity and expression in many solid tumors as
well as the ability of this enzyme to reductively bioactivate many quinone-based
antitumor agents have centered the focus on NQO1 as a proper target for bioreductive
therapy.1,4,6,8

1.2

NAD(P)H:Quinone Oxidoreductase 1 (NQO1)

NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, DTD, QR1 or EC
1.6.99.2) is a widely distributed homodimeric flavoenzyme composed of two closely
associated monomers of 273 residues, each containing one molecule of the noncovalently
attached FAD cofactor molecule that is required for NQO1 catalytic activity.9-13 This
enzyme was first detected by Ernster and Navazio in 1956 and they presented their
findings on the enzyme at both the Swedish Biochemical Society meeting and Federation
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Meetings in the United States in 1958.14 The purification procedure for NQO1 from rat
liver and assay conditions, stability, inhibitors, activators and electron acceptors of the
enzyme were detailed by Ernster et al. in 1962.15 This obligate two-electron reductase is
present in cytosol (> 90%)16 and nucleus,17 and catalyzes a nicotinamide nucleotide
[NAD(P)H]-dependent two-electron reduction14,18 and the bioactivation of many
quinone-based anticancer compounds. Antitumor quinones including streptonigrin
(SN),19-21 mitomycin C (MMC),22,23 β-lapachone (a 1,2-naphthoquinone analogue),24,25
various indolequinones such as EO9 ,26-28 and a number of aziridinylbenzoquinones such
as RH129-32 and diaziquone (AZQ)33-35 are bioactivated by NQO1 (Chart 1.1).
1.2.1 NQO1 Structure. The crystal structures of the apo human NQO112,13 and
human NQO1 in complex with several agents have been reported.13,36-38 Each monomer
of the physiological dimer of NQO1 is composed of two distinct domains, a major
catalytic (1-220 residues) and a small C-terminal domain (221-273 residues).10,13,37,38
Two equivalent active sites are located at the dimer interface and are formed by portions
of both subunits.12,13 The active site of the enzyme is a hydrophobic and plastic pocket
that is capable of forming van der Waals and hydrogen bond interactions with quinone
compounds.13,37,39
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Chart 1.1. Chemical structures of qninone-based bioreductive antitumor agents.
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In the NQO1 active site, Tyr-126, -128 and Phe-178 amino acid residues form the
roof of the active site.13,37 The floor is made up of the isoalloxazine ring of FAD, while
Trp-105, Phe-106 and -178 residues form the internal wall and His-161, Gly-149 and 150 residues flank the cavity.13,37 Gly-149, -150 and His-194 residues also restrict the
entrance to the active site.13
1.2.2 NQO1 Enzymatic Mechanism. The substrate binding pocket of the
enzyme sequentially binds NAD(P)H (electron donating cofactor) and the quinone
substrate during an obligatory two-electron reduction process known as a ping-pong
mechanism (Figure 1.1).10,13,37 In the first half of the reaction a hydride ion from
NAD(P)H is transferred to the N5 of FAD followed by the release of NAD(P)+.10,40,41
The hydride donation from the FADH2 N5 to the quinone hydride-acceptor substrate
(across a 4 Å distance41) can then be done at either a carbonyl oxygen or ring carbon
followed by hydroquinone release. The remaining proton can be provided by Tyr-126, 128 or His-161.10,40,41 Quinone substrates can bind to the NQO1 active site in more than
one orientation, and homologous compounds with different substituents may bind to the
NQO1 active site in different orientations.37,40
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Figure 1.1. Ping-pong enzymatic mechanism of NQO1.42
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1.2.3 NQO1 Overexpression in Tumors. One crucial element of enzymedirected bioreductive drug development in cancer therapy is the presence of high levels
of reductase enzymes in tumors.1,3-7 Increased NQO1 enzymatic activity has been
reported in human lung, breast, colon and liver primary solid tumors compared to
corresponding normal tissues from the same patients.43 The NQO1 enzymatic activity in
the lung adenocarcinoma sample of a patient was found to be 123-fold higher than the
adjacent uninvolved tissue.43 Lung tumors from cancer patients also displayed up to 80fold higher NQO1 activity than the paired surrounding normal tissue.44 Comparison of
the NQO1 gene expression in liver biopsy samples of normal individuals and cancer
patients determined a 50-fold increase in NQO1 mRNA level in liver tumors compared to
normal human liver tissue.45 It has also been suggested that the NQO1 gene is expressed
at high levels in mouse hepatoma cells versus normal mouse liver.45 A good correlation
between NQO1 mRNA levels and enzymatic activity has been observed in many lung
tumor cell lines.44 These studies have clearly demonstrated increased NQO1 enzymatic
activity and mRNA levels in various tumor tissues versus normal counterparts.
Increased levels of NQO1 protein in tumor tissues have also been reported. One
group utilized Western blot analysis for immunological detection of NQO1 protein using
a mouse anti-human monoclonal NQO1 antibody in paired colorectal tumors and normal
peripheral tissues.46 They detected higher amounts of NQO1 protein in colorectal tumors
in comparison to related normal tissues.46 They also determined that there was an
excellent correlation between the levels of the enzyme and its activity in colon and gastric
carcinoma cell lines, and surgically removed colorectal adenocarcinoma tumors.46 In
addition, elevated levels of NQO1 protein in pancreatic cancer cell lines as well as a
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significant increase in the amount of the protein in human pancreatic adenocarcinoma
tumors compared to normal pancreas specimens have been observed .21 High levels of
NQO1 enzymatic activity, mRNA and protein in tumor versus normal tissues
demonstrated in these studies suggest that NQO1 is an important target for bioreductive
therapy.
1.2.4 NQO1 Polymorphism. One important element of enzyme-directed
bioreductive drug development is the individualization of patient treatment that can be
accomplished through identification of patients with appropriate enzymatic profiles.5,8
One means of individualizing patient therapy in the enzyme-directed approach is
pharmacogenetic analysis of polymorphisms in the reductase of interest.47 Since NQO1
is considered a good target in enzyme-directed bioreductive drug development, its
potential polymorphisms that affect NQO1 enzymatic activity would be anticipated to
impact quinone-based cancer therapy.47,48
The human NQO1 gene is approximately 20 kb long, possesses six exons with
five interrupting introns and is located on human chromosome 16q22.1.49-51 Traver et al.
have characterized an important polymorphism in the NQO1 gene (NQO1*2) in human
colon adenocarcinoma cells (BE) and human non-small-cell lung cancer (NSCLC) H596
cells that results in the loss of NQO1 activity in these cell lines.52,53 They did not detect
the mutant NQO1 protein in the cytosol of BE and H596 cells utilizing immunoblot
analysis suggesting the possible cause for the lack of NQO1 activity was the lack of the
NQO1 protein.48,52,53 Both cell lines exhibited high levels of mRNA, but no NQO1
enzymatic activity.48,52,53 This polymorphism, NQO1*2/*2, is a homozygous C to T
point mutation at position 609 of the coding region of the human NQO1 gene, exon 6.52,53
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This mutation results in a protein with a proline to serine substitution at position 187 that
possesses only 2-4% of the enzymatic activity of the wild-type NQO1.52,53 The
NQO1*2/*2 genotype possesses an incidence of 4-22% varying across different ethnic
groups.
The NQO1*2 polymorphism can highly impact bioreductive cancer therapy.48
One clinical study determined that among patients with peritoneal cancer that were
administered MMC, individuals with heterozygous or homozygous NQO1*2
polymorphisms exhibited reduced survival compared to those with the wild-type NQO1
genotype (NQO1*1/*1).54 The authors also confirmed genotype-phenotype relationships
such that individuals with the heterozygous genotype displayed less tumor NQO1 activity
in comparison to patients with the wild-type genotype.54 This study highlights the
significant impact that NQO1*2 polymorphism could have on the outcome of NQO1directed quinone anticancer therapy. Genotyping of patients to identify the NQO1*2
polymorphism could greatly contribute to individualization of patient treatment in
bioreductive cancer therapy.47
1.2.5 Reductive Activation of Antitumor Quinones by NQO1. The role of
NQO1 in the reductive activation of many quinone-containing bioreductive agents has
been reported. SN, MMC, EO9, RH1 and AZQ are examples of quinone-based
bioreductive agents that are activated by NQO1. Siegel et al. determined MMC-induced
DNA interstrand cross-link formation in human colon adenocarcinoma HT-29 cells
(NQO1-rich) when compared to BE cells (NQO1-deficient).22 They observed higher
levels of sensitivity to MMC-induced cytotoxicity in HT-29 cells versus BE cells.22
NQO1-mediated metabolism of MMC in a cell-free system has also been shown to result
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in the bioactivation of MMC, and induction of DNA adduct formation and DNA crosslinking.23 In addition, Beall et al. reported selective toxicity of a number of
indolequinones and mitosenes toward the NSCLC H460 cell line with high NQO1
activity compared to H596 cells with no measurable NQO1 activity,28 and the
indolequinone EO9 was found to be 92 times more toxic to the H460 cells compared to
the H596 cells.55 Another bioreductive quinone anticancer agent, SN, exhibited similar
preferential cytotoxicity toward H460 cells versus H596 cells (86-fold).56 Furthermore,
SN displayed higher levels of toxicity (similar to MMC) and DNA strand breaks in HT29 cells compared to BE cells.19 These studies determine that NQO1-mediated activation
of bioreductive agents MMC, SN and EO9 in NQO1-rich versus NQO1-deficient cancer
cells results in the selective toxicity of these agents toward NQO1-rich cells.
Bioreductive activation of aziridinylbezoquinones by NQO1 has also been
reported. BE and HT-29 cells have been used as a model system to investigate
bioreductive activation of AZQ by NQO1.34 In this study, DNA interstrand cross-linking
by AZQ was examined in both BE and HT-29 cell lines.34 A high degree of dosedependent cross-linked DNA was detected in HT-29 cells whereas low levels of DNA
cross-links were observed in BE cells after exposure to AZQ at the same
concentrations.34 Significant generation of cross-linked DNA in the human breast
adenocarcinoma cell line MDA468 transfected by wild-type NQO1 (NQ16) was observed
after treatment by another bezoquinone, RH1, at a concentration as low as 50 nM.30
However, very low induction of DNA cross-linking was observed in the parental cell line
(MDA468) that had no measurable NQO1 activity after exposure to RH1 at a
concentration 10-times higher than the concentration used in NQ16 cells.30 One group
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also determined activation of RH1 both in vitro and in vivo in NQ16 cell line and NQ16
xenografts, respectively.31 The authors observed a significant dose-dependent reduction
in tumor size in mice bearing NQ16 human tumor xenografts after treatment with low-,
medium- and high-dose RH1.31 In contrast, tumor growth inhibition in mice with NQO1deficient MDA468 xenografts was demonstrated only at high doses of RH1.31
Selective formation of DNA interstrand cross-links, adducts and strand breaks by
the quinone-based anticancer agents, and their preferential cytotoxicity in different
NQO1-rich versus NQO1-deficient cells in these studies demonstrate the important role
that NQO1 plays in the bioreductive activation of these agents. This is of primary
interest since agents that are bioactivated by NQO1 can result in selective tumor toxicity
without high levels of toxicity to normal tissues.9 This characteristic of NQO1 is
considered as one major element of enzyme-directed bioreductive drug development.5

1.3

Antitumor Quinones

Quinones are among the most important and largest groups of natural and
synthetic anticancer drugs.57 Two general mechanisms of quinone-based toxicity have
been identified; redox cycling and macromolecule alkylation reactions.57
1.3.1 Quinone-based Bioreductive Agents in Use or in Clinical Trials. SN,
MMC, EO9, AZQ and RH1 are examples of quinone-based bioreductive agents that are
currently in use, clinically evaluated or in clinical trials.1
SN is a natural aminoquinone antitumor antibiotic that has demonstrated
antitumor activity toward a broad range of tumors such as lung, head and neck, breast,
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lymphoma and melanoma.58 This drug was in clinical use until the 1970s when its use in
chemotherapy was discontinued due to high toxicity and severe bone marrow
depression.58 MMC, a naturally occurring antitumor bioreductive drug, is the only
quinone-containing alkylating agent that is currently in use in the clinic.1 MMC
possesses activity against stomach, lung, prostate, head and neck, bladder and breast
tumors.1,9 However, its dose-limiting toxicity, delayed bone marrow suppression, has
greatly restricted the clinical use of this drug.1,9,59
The aziridinylbenzoquinone AZQ with good solubility, underwent clinical trials
for the treatment of central nervous system (CNS) tumors.1,9,59 Although it displayed
some antitumor activity against brain tumors, it was not significantly more effective than
other agents already in use.9,59 AZQ also exhibited dose-limiting toxicities such as
leukopenia and thrombocytopenia.1,59 EO9, a synthetic analogue of MMC, is an
improved substrate for NQO1 compared to MMC.9 It was selected for clinical trials in
the early 1990s due to its excellent antitumor activity in preclinical studies and lack of
bone marrow suppression.1,9 Despite the promising preclinical results, EO9 failed to
exhibit any antitumor activity against breast, colon, gastric, pancreatic and non-small-cell
lung cancer in phase II clinical trials.1,9 EO9’s failure in the clinical trials has been
attributed to its short half-life and poor tissue penetration.1,9,59 RH1, a water-soluble
aziridinylbenzoquinone, is an excellent substrate for NQO1 and is currently in clinical
trials.9 Bone marrow suppression and inflammation in the injection site have been
reported as the RH1 toxicities.9 Due to the high levels of toxicity of these compounds
there is an ongoing need for discovery of improved bioreductive quinone-based antitumor
agents with higher safety profiles.
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1.3.2 Lavendamycin. Lavendamycin, a naturally occurring 7-aminoquinoline5,8-dione antitumor antibiotic, was first isolated from the fermentation broth of
Streptomyces lavendulae (strain C-22030) by Balitz et al. in 1981 and was reported in
1982.60 They characterized the producing culture, fermentation and isolation conditions
of lavendamycin, and tested its biological activity.60 Prior to this report, the structure of
lavendamycin was determined and reported by Doyle et al. in 1981.61 This study
determined that lavendamycin is a 7-aminoquinoline-5,8-dione pentacyclic structure with
two moieties including quinoline-5,8-dione and indolopyridine (β-carboline) (Chart
1.1).61
Lavendamycin has been shown to possess both in vitro and in vivo antitumor
activity.60,62 In an in vivo study, this compound exhibited antitumor effects against P388-J leukemia ascites cells implanted into BDF1 mice (i.p.) when administered on a
daily basis for 9 days.60 Lavendamycin increased the median survival time (MST) of the
treated animals compared to control animals that received saline.60 Lavendamycintreated animals also displayed higher MST values and MST treated/MST control x 100
ratios when results were expressed in days and as percentage of control MST,
respectively.60 In addition, lavendamycin has displayed in vitro antiproliferative
activities against cancer cell lines such as P388 murine leukemia, MKN45 human gastric
carcinoma and WiDr colon adenocarcinoma cells.62 The maximum tolerated dose of
lavendamycin in mice is 12.8 mg/kg which is 32 folds higher than that for SN and is
therefore less toxic than SN.60 Despite the interest in lavendamycin as an antitumor
agent, this agent was precluded from preclinical development due to its poor aqueous
solubility and its toxicity toward normal human cells.63-65
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1.3.3 Lavendamycin Analogues and Significance. Lavendamycin has been the
focus of several synthetic studies to elucidate the structural features that are required for
its cytotoxic activity and to develop improved analogues with potent antitumor properties
and lower animal toxicity. Initial structure-activity relationship (SAR) studies have
demonstrated that the essential moiety for the cytotoxic activity of lavendamycin is the 7aminoquinoline-5,8-dione moiety.63 In a recent study in vitro and in vivo antitumor
effects of several lavendamycin analogues were tested.65 Four analogues, MB-21, -47, 121 and -311, suppressed the clonogenic survival of A549 human lung carcinoma cells at
concentrations less than 100 nM with MB-121 being the most potent analogue that
inhibited A549 colony growth by 70% at a concentration of 100 nM.65 Also, the colony
outgrowth of the cells was reduced by 70% at 10 nM and by 100% at 100 nM
concentration of the lavendamycin analogue MB-97.65 Although PC-3 human prostate
cancer cell line is rather resistant to antitumor effects of many antitcancer agents, these
cells displayed sensitivity toward the cytotoxic properties of MB-97 at a concentration as
low as 10 nM.65 MB-97 also exhibited promising antiproliferative activities against
cancer cell lines of the National Cancer Institute (NCI) 60-cell line panel including colon,
ovarian and renal cells, and cancer cells in a hollow fiber tumorigenesis assay.65
It has been reported that lavendamycin analogues possess low animal toxicity
especially compared to SN and the parent lavendamycin compound.64,66 The NCI in vivo
studies have reported that the maximum tolerated dose of three lavendamycin analogues
MB-22, -76 and -97 in mice is 400 mg/kg which is 31 and 1000 times higher than that for
lavendamycin and SN, respectively.64,66 The lavendamycin analogue MB-51 greatly
reduced tumor volume (up to 80%) in mice bearing tumor xenografts at a daily dose of
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300 mg/kg for 10 days without exhibiting drug-related weight loss or lethality.67 A
recent study also demonstrated that the normal rat kidney epithelial cell line (NRK-52E)
exhibited much less sensitivity to several lavendamycin analogues compared to the tumor
cells with the same origin.64 When lavendamycin analogues MB-50 and -51 at a daily
dose of 300 mg/kg and MB-21 at a daily dose of 100 mg/kg were administered to nude
mice for eight and seven days, respectively, no drug-related deaths or toxicity were
observed.64 Analogues MB-21, -50 and -51 inhibited tumor growth in nude mice by 69,
88 and 78%, respectively, when administered at 100, 150 and 300 mg/kg for 7, 8 and 8
days, respectively.64 These studies demonstrate remarkable low in vivo toxicity of
lavendamycin analogues and highlight them as appropriate candidates for anticancer drug
development.
1.4

NQO1 X-ray Crystal Structures and Molecular Docking Studies
1.4.1 NQO1 Crystal Structures. X-ray crystallography is the principal source

to acquire structural information for protein-ligand complexes.68 X-ray crystal structures
of protein-ligand complexes have played a key role in drug discovery and development
for therapeutically relevant target proteins in recent years.69-71 Complex crystal structures
of protein-ligand have provided researchers with useful information on the ligand
orientation in the active site and corresponding protein-ligand interactions.69 These data
can in turn contribute to SAR studies and subsequent structure-based ligand design and
optimization.69 NQO1 crystals for the purpose of x-ray crystallographic studies were first
prepared from mouse and rat liver in the late 1980s by Amzel et al. and Ysern et al.72,73
They reported preliminary x-ray diffraction data on NQO1 crystals.72,73
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Detailed structural information of NQO1 has been a crucial factor in proper
understanding of the catalytic mechanism (ping-pong mechanism) of the obligatory twoelectron reduction by NQO1.10 Li et al. employed three-dimensional (3D) crystal
structures of NQO1 to elucidate the enzymatic ping-pong mechanism of NQO1.10 In
1995, They determined the crystal structure of rat liver NQO1 by x-ray diffraction to a
resolution of 2.1 Å (Protein Data Bank = PDB ID: 1QRD).10 They prepared two complex
NQO1 crystal structures, complex I containing both Cibacron blue (a potent inhibitor of
NQO1) and duroquinone, tetramethyl-1,4-benzoquinone, and complex II containing
NADP+.10 Comparison of the two complexes indicated that duroquinone overlaps the
position occupied by the nicotinamide ring of NADP+.10 This clearly explains the pingpong catalytic mechanism of NQO1 where substrate binding and reduction cannot occur
until NADP+ is released.10 They also determined that Cibacron blue occupied the same
position as the rest of the NADP+, but did not overlap the duroquinone position.10 This
observation shed light on the inhibition pattern of NQO1 by Cibacron blue that is
competitive with respect to NADH and noncompetitive in regard to quinone substrates.10
The information obtained in another study from the 3D crystal structures of
human NQO1 in complex with RH1, EO9 and ARH019 (PDB ID: 1H66, 1GG5 and
1H69, respectively) determined that antitumor quinones can bind to NQO1 in different
orientations.37 The study of these complex crystal structures further determined that
NQO1 possesses a highly plastic active site that can accommodate quinone compounds of
different sizes.37 The authors suggested that these complex crystal structures could
provide crucial insights for the optimization of bioreductive anticancer quinones.37 They
demonstrated that amino acid residues Tyr-126, -128 and His-161 can interact with the
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quinone substrates inside the active site and stabilize the binding.37 This group also
determined the crystal structure of NQO1 in complex with duroquinone to 2.5-Å
resolution.13 They subsequently defined the NQO1 active site structure and demonstrated
the importance of Trp-105, -106, Tyr-126, -128 and Phe-178 residues in formation of
interactions with the ligand.13 The crystal structure of NQO1 in complex with
indolequinone ARH019 was recommended by this group as a potential model for docking
studies of other anticancer quinones including SN.37
The binding characteristics of lavendamycin analogues in the NQO1 active site
are not yet known. Due to the fact that there are no available complex crystal structures
of NQO1 with lavendamycin analogues, one can utilize crystal structure-based molecular
docking studies to obtain detailed understanding of the molecular basis of interactions of
these compounds with NQO1.
1.4.2 Molecular Docking Studies of Bioreductive Quinones with NQO1.
Molecular modeling studies of quinone-based antitumor compounds with NQO1 could
indicate structural limitations on the potential substrates for the enzyme.74 Docking
studies could greatly assist with SAR studies and structure-based design of novel NQO1
quinone substrates.1,74 These studies could also predict the preferred orientation of
quinone antitumor compounds within the active site.40 Molecular docking studies also
assist researchers to obtain insights into the role that amino acid residues play in substrate
binding affinity.75
The indolequinone SAR study by one group demonstrated that when the
aziridinyl group of EO9 or the methoxy group of another indolequinone at the C5
position was replaced with methylaziridine, substrate specificity of the compounds was
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reduced.74 They were able to explain this observation by performing molecular modeling
studies of the indolequinone EO9 with NQO1.74 They determined that the Trp-106
played a major role in forming favorable van der Waals interactions with an aziridinyl or
a methoxy group at the C5 position.74 However, methylaziridinyl substituent at C5
created steric interactions with the Trp-106 residue resulting in unfavorable positioning
of the quinone moiety for reduction.74 In addition, Zhou et al. observed that when the
number of fused rings in the quinone nucleus of quinone compounds increased from one
ring in benzoquinones to two or three rings in naphthoquinones or anthraquinones,
respectively, the substrate specificity of the compounds was improved.40 They took
advantage of docking studies to demonstrate the importance of π-ring stacking in
determination of ligand binding affinity.40 Another group designed a series of quinone
substrates including dipyrroloimidazobenzimidazole and dipyridoimidazobenzimidazole
systems as potential good substrates for NQO1 compounds.75 They then modeled these
substrates into the NQO1 active site to investigate the correlation of docking data with
the substrate specificity of the compounds.75 The correlation of the docking models with
biological data provided the researchers with information regarding structural
requirements of the substrates.75 They observed that derivatives with unsubstituted
pyrido or pyrrolo rings, or with one acetate group on the rings were excellent substrates
for NQO1.75 Docking models displayed that the pyrido or pyrrolo ring of derivatives
bearing no or only one substituent could intercalate between and form favorable van der
Waals interactions with the Trp-105 and Phe-106 residues. However, derivatives with
substituents on both rings created steric interactions with the residues leading to poor

18

substrate specificity of these compounds.75 All these studies took advantage of docking
studies to explain observed substrate specificity of ligands and the related SAR data.
Molecular docking methods have become very useful tools in structure-based
ligand design because they provide information on the binding events and key
interactions between a known or newly designed ligand and its target protein.
Understanding these interactions is crucial to the success of drug design for bioreductive
antitumor quinone development.

1.5

Structure-based Ligand Design

Structure-based ligand design - also known as structure-based design or rational
ligand design - is a process that involves the optimization of ligand affinity and logicbased transformation of hit compounds to candidate drugs.68,76 The theory behind the
structure-based design process is that development of improved ligands will result in
higher binding affinities and higher activities against the biological targets.77,78 The 3D
structure of therapeutic targets is the starting point in this process and due to increasing
availability of these structures, structure-based design has gained momentum in recent
years.77,78 This process utilizes information obtained from an available 3D structure of a
biological target-ligand complex to design new drugs for human diseases.77 In a practical
structure-based design process computational docking tools are very useful in extracting
the information about binding events.77,78 They are utilized to characterize the type of
interactions between a known or designed ligand and the target protein.77,78 Use of in
silico (computer-based) methods in structure-based design entails a sequence of steps
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such as coordinate preparation of target molecule, docking and post-docking analysis to
extract the required structural information.76 This contributes to the design of improved
ligands from which a small, most promising group can be selected to be synthesized and
tested.68,77 It has been reported that on average it takes 14-15 years and hundreds of
millions of dollars for a hit compound to evolve to an approved drug.76,77 Computational
methods including docking programs and ligand scoring functions used in drug design
can accelerate this process and decrease high expenses of drug discovery and
development.77 The discovery of important classes of drugs such as HIV-protease
inhibitors, carbonic anhydrase II inhibitors, and late-clinical-stage candidates including
inhibitors of human non-pancreatic secretory phospholipase A2 has been greatly
facilitated by the structure-based design process.68

1.6

Redox-cycling Bioreductive Antitumor Quinones

NQO1 plays a major role in the bioactivation of several quinone-based anticancer
agents including SN,19,20 MMC,22 β-lapachone,24 AZQ33-35 and RH1.30,31 The
hydroquinone produced after the two-electron reduction of these agents is the
biologically active form that can cause DNA alkylation and/or oxidative stress.1,24,79
Quinones are powerful redox active agents that can undergo redox cycling, which is the
enzymatic reduction of quinones and subsequent auto-oxidation of the reduced forms to
parent compounds with concomitant generation of superoxide anion radical (O2-.) .79,80
When quinones undergo redox cycling following a two-electron reduction by NQO1, the
corresponding redox active hydroquinones can react with molecular oxygen through a
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one-electron oxidation process to yield semiquinones and O2-..79,80 Semiquinones can
then react with molecular oxygen to generate O2-. and auto-oxidize back to parent
quinones.79,80
Produced O2-. in this process is a propagating species that can dismutate into
hydrogen peroxide (H2O2) with ultimate production of extremely toxic hydroxyl radicals
(OH.).9,42,58,81-83 This NQO1-mediated redox-cycling process of quinones can produce
large quantities of reactive oxygen species (ROS).83 Excessive levels of produced ROS
in cells can overpower the antioxidant defense systems and modulate the intracellular
redox balance leading to a situation known as oxidative stress.84,85
Many studies have demonstrated the NQO1-mediated redox-cycling ability of
anticancer quinone-based agents. Hydroxyethylaminoalkylamino-substituted
anthraquinones (AQs) such as 1-AQ and 1,8-AQ have displayed redox-cycling
characteristics in NQO1-rich human breast cancer MCF-7 cells.86 Also, NQO1-mediated
ROS and semiquinone formation by AZQ, hydroxyl radical formation by a variety of
quinone antitumour compounds and ROS formation by anthraquinone-based antitumour
agents in the presence of purified rat liver NQO1 and NQO1-rich MCF-7 cells have been
determined.35,87-89 These studies have demonstrated that the hydroquinone form of these
quinone agents, following reduction by NQO1, undergoes a two-step one-electron
oxidation process with concomitant production of the damaging species such as
semiquinones and ROS.
Indolequinones, naphthoquinones and quinolinediones are also among the
antitumor compounds that generate biologically active species after reduction by NQO1
via redox cycling. The ability of the indolequinone EO9 to redox cycle in the presence of
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purified rat Walker tumor cell NQO1 and NAD(P)H following a two-electron reduction
has been reported.90 Furthermore, Pink et al. determined that NQO1 reduces β-lapachone
to an unstable hydroquinone that can auto-oxidize back to the parent form, possibly
through a semiquinone intermediate.24 They proposed this redox cycling can cause
oxidative stress and cytotoxicity.24 SN, a prototypical and efficient redox-cycling
antitumor agent, can also produce large quantities of ROS after bioactivation by
NQO1.19,56,83 The ability of SN to undergo redox cycling after bioactivation by NQO1 in
NQO1-rich HT-29 cells and to produce hydroxyl radical-mediated DNA strand breaks
has been reported.19 These studies suggest that NQO1-mediated metabolism of redoxcycling antitumor quinones can alter the intracellular redox balance, cause DNA damage
and the corresponding cytotoxicity.
1.6.1 Redox-cycling Antitumor Quinones and Intracellular Redox State. The
intracellular redox responses and antioxidant defense systems in neoplastic cells play a
major role in their protection against antitumor agents.79,85 Chemotherapeautic agents
that possess the ability to alter the intracellular redox environment in favor of oxidative
stress can induce apoptosis and be utilized in cancer treatment.79,85 It has been
determined that the production of ROS is an important mechanism of cytotoxicity of
many antitumor agents.85 Tumor cells employ antioxidant defense systems such as
reducing species to neutralize ROS and avoid potential ROS-mediated cellular damage
and subsequent induction of apoptosis.85 Glutathione (GSH), a non-protein cellular thiol,
is a key component of the intracellular defense system against oxidative stress and is
involved in detoxification of ROS.85 The ability of cells to maintain GSH levels during
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an oxidative challenge is of vital importance in the maintenance of cellular function,
integrity and viability.91
Thiol oxidation by the ROS produced during metabolism and redox cycling of
quinones is a key feature of quinone toxicity.81 GSH oxidation and depletion in a cellfree system due to NQO1-mediated redox cycling of AZQ have been demonstrated.92
Menadione, a redox cycling 1,4-naphthoquinone, caused oxidative stress in cultured
human-derived endothelial cells (EA.hy926) that was assessed by oxidation of
intracellular dihydrofluorescein.93 This compound at a concentration of 100 µM
significantly reduced the intracellular GSH levels in EA.hy926 cells after a 30-minute
exposure period.93 GSH oxidation and consumption by O2-. during NQO1 catalysis of 2methylmethoxy-1,4-naphthoquinone have also been observed.94 The reduction of 2methylmethoxy-1,4-naphthoquinone by NQO1 in this study was associated with
formation of calf thymus DNA strand breaks that were suppressed by the presence of
superoxide dismutase and catalase by 85-90%.94 These findings suggest that intracellular
redox state alteration can occur as the result of metabolism of redox-cycling quinones.
The ability of a cell to maintain a proper oxidant-antioxidant balance can determine the
outcome of an apoptosis-triggering signal.79 Production of ROS and depletion of GSH
can lead to oxidative stress with subsequent induction of apoptosis in cancer cells.85
1.6.2 Redox-cycling Antitumor Quinones and Oxidative DNA Damage.
DNA has been recognized as the principal target of quinone-based antineoplastic
compounds.57 Quinone redox cycling can generate excessive amounts of ROS and when
the generated ROS are not adequately neutralized, they become involved in many
oxidative stress-related events such as DNA strand breaks or oxidative DNA damage.57,95
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Hydroxyl radical, the most destructive species among oxygen radicals, is highly toxic,
capable of attacking DNA, and oxidizing guanine bases resulting in the formation of
mutagenic 8-hydroxy-2'-deoxyguanosine (8-oxo-2dG) lesions.57 Among the purine and
pyrimidine bases of DNA, guanine is the most sensitive base to oxidation.96,97 During an
oxidative attack, a hydroxyl group is added to the eighth position of the guanine base
generating an 8-oxo-2dG oxidative adduct.96 8-Oxo-2dG is one of the most frequently
studied and predominant forms of oxidative DNA damage.98 During DNA replication,
the modified base, 8-oxo-2dG, pairs with adenine instead of cytosine, resulting in G:C →
T:A transversion mutations.97
The most important reactions involving quinones are generation of ROS and
DNA damage.79 It has been reported that redox cycling of AZQ produces 8-oxo-2dG
lesions (unpublished data).95 Pagano et al. also demonstrated significant production of 8oxo-2dG in sea urchin embryos after exposure to the antitumor quinone MMC at a
concentration as low as 1 µM.99 Their results further associated MMC-induced toxicity
with the induction of oxidative stress and oxidative DNA damage.99 Investigation of
DNA damage production by antitumor agents is important since it has been known for
more than 25 years that DNA damage can induce apoptosis.100
1.6.3 Redox-cycling Antitumor Quinones and Apoptosis. Apoptosis, or
programmed cell death, can be induced by DNA damage,100 and plays a key role in tumor
suppression and in regulation of cell populations.101 Many cancer cells develop strategies
to deregulate or circumvent apoptosis and these are important contributing factors in
tumor development.101 Therefore, the ability of anticancer agents to efficiently induce
apoptosis in tumor cells is of great importance. Although, apoptosis can be induced in
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various ways, it can be distinguished by highly conserved morphological characteristics
including nuclear condensation, cell shrinkage and DNA fragmentation into
oligonucleosomes.101
Quinones are an important group of anticancer agents that induce apoptosis via
redox cycling.102 Since the mechanism of cytotoxicity of redox-cycling quinones is due
to free radical production, induction of oxidative stress and DNA damage, quinones are
considered as powerful inducers of apoptosis.79 Induction of apoptosis is the principal
mechanism of cytotoxicity of β-lapachone in human prostate103 and breast104 cancer cells.
NQO1 activity is a key determinant of β-lapachone-mediated cytotoxicity and apoptosis
induction in NQO1-expressing prostate cancer cells.25 In addition, MMC, MeDZQ (an
aziridinylbenzoquinone) and SN can preferentially induce NQO1-mediated apoptosis in
NQO1-rich HT-29 cells compared to NQO1-deficient BE cells.20 Therefore, an
association between the NQO1 activity in these cells and the corresponding cytotoxicity
and apoptosis induction by these quinone anticancer compounds is observed.

1.7

In Vitro Models for NQO1-directed Bioreductive Anticancer Quinone
Development

To examine the importance of the role of NQO1 in the bioactivation of quinonebased antitumor agents, a common approach has been to use tumor cell lines that differ in
NQO1 expression levels.22,28,34,56 When non-isogenic paired cell line models are utilized,
the results of bioreductive activation of compounds by NQO1 are prone to the effects of
confounding factors including genotypic differences in the cell lines.31,105,106 Differences
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in activities of other reductases and in the expression of genes that impact drug
metabolism are examples of different genotypic profiles of non-isogenic cell lines.31,105
To better control and study the role of NQO1 in the bioreductive activation of antitumor
quinones, isogenic cell line pairs that only differ in NQO1 expression have been
developed.31,105,106
An isogenic cell model for NQO1 expression employing BE cells was established
by Sharp et al in 2000.105 They stably transfected BE cells, which possess no NQO1
activity due to a disabling genetic polymorphism (NQO1*2/*2), with an expression
vector containing human NQO1 cDNA.105 They demonstrated stable high-expression
levels of NQO1 in the transfected cells (BE2) using Western blot analysis and enzyme
activity assay.105 They did not observe any differences in the cell lines in regards to the
activity of other reductases that may be involved in drug metabolism.105 This group
observed selective toxicity of EO9 and SN towards NQO1-rich clones compared to
NQO1-deficient BE cells.105 Similar to this model, stably transfected BE-NQ cells that
express wild type NQO1 were also developed using BE cells by a second group in
2001.106 They demonstrated using MTT and clonogenic assays that BE-NQ cells were
more susceptible to the cytotoxic effects of SN and RH1 in comparison with BE cells.106
These pairs of isogenic cell lines have been suggested as proper models for NQO1mediated mechanistic studies and antitumor quinone development.105,106
Dehn et al. have also developed and validated an isogenic cell line pair using
human breast adenocarcinoma cells, MDA468, which lacks NQO1 activity due to the
same homozygous point mutation in the NQO1 gene.31 They stably transfected MDA468
cells with human wild-type NQO1 cDNA to generate the NQ16 cells that express very
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high levels of NQO1.31 Levels of reductases, soluble thiols and superoxide dismutase
were compared in both cell lines and no significant differences in the corresponding
levels were determined.31 The selective toxicity of RH1 and SN towards NQ16 cells
compared to NQO1-deficient MDA468 cells demonstrated functional validation of this
isogenic model.31

1.8

Hypothesis

Using SAR, metabolism, in vitro cytotoxicity studies, and computer-aided and
structure-based ligand design methods, this project studied NAD(P)H:quinone
oxidoreductase (NQO1)-directed lavendamycin antitumor agents. We hypothesized that
NQO1 could bioactivate good lavendamycin substrates resulting in their redox cycling
with concomitant induction of oxidative stress. The activated lavendamycin substrates
would be expected to display selective toxicity towards NQO1-rich cancer cells via thiol
depletion, oxidative DNA damage and apoptosis induction. In addition, development of
an in silico model of the NQO1 active site in conjunction with SAR studies would highly
contribute to the structure-based design of more optimal lavendamycin substrates and
NQO1-directed lavendamycin antitumor agent development.

1.9

Specific Aims

1.9.1 Specific Aim I. Determine the role of NQO1 in the bioreductive
activation and cytotoxicity of lavendamycin analogues in NQO1-deficient (BE) and
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NQO1-rich (BE-NQ) cancer cells and indicate the structural requirements for substrate
specificity of these compounds - SAR studies (Chapter 2).
1.9.2 Specific Aim II. Develop an in silico NQO1 active site model and perform
docking studies to facilitate NQO1-directed lavendamycin antitumor agent development
and structure-based design of novel lavendamycin analogues (Chapters 3 and 4).
1.9.3 Specific Aim III. Investigate mechanisms of NQO1-mediated selective
cytotoxicity of good lavendamycin substrates towards NQO1-rich BE-NQ cell line
compared to BE cells (Chapter 5).
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Chapter 2
Novel Lavendamycin Antitumor Agents: Electrochemistry, Structure-metabolism
Studies and In Vitro Cytotoxicity with NAD(P)H:Quinone
Oxidoreductase 1 (NQO1)

2.1

Abstract
A series of novel lavendamycin analogues bearing various substituents were

evaluated as potential NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor
agents. The effects of substituents and functional group changes on the metabolism
(reduction efficiency) of these analogues by recombinant human NQO1 were studied.
Lavendamycin analogues reduction was monitored using a spectrophotometric assay in
which the rate of reduction of cytochrome c was quantified at 550 nm. Structuremetabolism studies demonstrated that small to medium-size substituents at the
quinolinedione-7-position were well tolerated whereas large, bulky substituents were not.
Substituents at the quinolinedione-6-position of lavendamycins generally reduced rates of
reduction compared to compounds with no substituents at this position. Small or large
substituents at the indolopyridine-2'-position were tolerated. Addition of NH2 and
CH2OH groups at the quinolinedione-7-position and indolopyridine-2'-position,
respectively, had the greatest positive impact on substrate specificity. The best and
poorest lavendamycin substrates were MB-353 (2′-CH2OH-7-NH2 derivative) and MB323 (2′-CONH2-7-NHCOC3H7-n derivative) with reduction rates of 263 ± 30 and 0.1 ±
0.1 µmol/min/mg NQO1, respectively. The electrochemical reduction potentials of the
lavendamycin analogues were measured by cyclic voltammetry. The findings suggest a
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more important role of lavendamycin substituent size and steric influence compared to
electronic effects to determine the reduction efficiency of the compounds by NQO1. The
cytotoxicity toward human colon adenocarcinoma cells with either no detectable NQO1
activity (BE) or with high NQO1 activity (BE-NQ) was determined in representative
lavendamycin analogues. The best lavendamycin substrates for NQO1 were also the
most selectively toxic to the NQO1-rich BE-NQ cell line compared to the NQO1deficient BE cells with the 2′-CH2OH-7-NH2 derivative (MB-353) being 11 times more
toxic to BE-NQ cells versus BE cells.

2.2

Introduction

A large number of antitumor agents have been discovered empirically without the
theoretical understanding of the corresponding molecular targets or mechanisms of
action.1 A rational approach to chemotherapy, selective cancer therapy, takes advantage
of molecular targets that are unique to cancer cells utilizing the differences existing
between cancer and normal cells.1,2 In selective cancer therapy antitumor agents are
designed with pre-existing knowledge of the biochemical mechanism of the drug action.3
This approach is aimed to destroy cancer cells via exclusive interaction of antitumor
agents with unique tumor targets (selective toxicity) while posing minimal toxicity to
normal cells.2-5 One approach to achieve antitumor selectivity is enzyme-directed
bioreductive drug development.2,4,5 In this approach, selective toxicity can be obtained
by identifying reductase enzymes that are overexpressed in tumor cells when compared to
normal cells.2,4-6 Then, bioreductive agents that are substrates for and bioactivated by the
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related reductase can be designed to selectively target the tumors with the up-regulated
reductase.2,4-6
One proper candidate for enzyme-directed bioreductive drug development is
NAD(P)H:quinone oxidoreductase 1 (NQO1). NQO1 is a ubiquitous homodimeric
flavoenzyme that possesses two closely associated monomers of 273 residues. Each
monomer contains one molecule of the FAD prosthetic group that is required for NQO1
enzymatic activity.7-11 This obligate two-electron reductase is a mainly cytosolic enzyme
(> 90%),12 although lower amounts of this reductase have been detected in nucleus,
mitochondria and endoplasmic reticulum.13 NQO1 catalyzes a nicotinamide nucleotidedependent two-electron reduction14,15 and the bioactivation of quinone anticancer
compounds such as quinolinequinones, mitomycins, indoloquinones and
aziridinylbenzoquinones.16-20 In addition, marked elevations in NQO1 activity and
mRNA content in primary tumors from lung, liver, colon and breast,21 and lung,22 liver,23
brain24 and colorectal25 tumors have been reported. These suggest that antitumor
compounds that are bioactivated by NQO1 can be selectively toxic to tumors that
overexpress this enzyme.
Lavendamycin (Chart 2.1), a bacterially derived quinolinedione antibiotic, was
isolated from the fermentation broth of Streptomyces lavendulae in 1981.26
Lavendamycin is structurally26,27 and biosynthetically28-30 related to streptonigrin (SN)
(Chart 2.1), another potent 7-aminoquinoline-5,8-dione antitumor antibiotic. Earlier
work has shown that the use of both of these antitumor agents as potential drugs has been
precluded due to their high degree of toxicity.27,31,32 However, in contrast to the parent
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compound, it has been found that a significant number of lavendamycin derivatives have
low animal toxicity but exhibit strong antitumor activity.33-35
Bioreductive enzyme-directed antitumor agent development depends on
identification of antitumor agents with high substrate specificity for target reductases.36
Several approaches have been applied to identify efficient quinone-based substrates for
NQO1, optimize the substrate specificity, and reduce the non-selective toxicity toward
normal tissues. A large number of metabolism studies of quinone-based anticancer
agents excluding lavendamycins with NQO1 have been performed during the last twenty
years to identify the most efficient quinone substrates for NQO1. One common approach
has been to investigate the effects of functional group alterations on reduction efficiency
and bioactivation of antitumor quinones by NQO1.36 This can assist in identification of
the structural features that confer substrate specificity and are required for selective
bioactivation of quinone compounds by NQO1 and their selective cytotoxicity.36,37 Many
studies reported that functional group changes in a series of indolequinone, 1,4naphthoquinone and benzoquinone mustard analogues significantly affected the substrate
specificity and selective cytotoxicity of the analogues towards NQO1-rich cell lines in
vitro.36-43
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Chart 2.1. Chemical structures of lavendamycin, streptonigrin and the lavendamycin
analogues with substituent positions indicated by R1, R2, R3 and R4.

O
CH3O

O

H2N
H2N

N

N
O
HN

CO2H

N
O

H2N

N

CO2H
CH3

HO

CH3

CH3O
OCH3

Lavendamycin

Streptonigrin

O
R2
R1

N

N
O
HN

R3
R4

Lavendamycin analogues
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This study was conducted to clarify the role of NQO1 in the bioactivation of
lavendamycin analogues. Specifically, the objectives were to perform structure-activity
relationship (SAR) studies to analyze the effects of functional group changes on the
reduction efficiency of lavendamycin analogues by NQO1 and to verify whether
activation by NQO1 resulted in selective cytotoxicity of these compounds toward NQO1rich cells. This is the first study that has been performed to verify structural features of
lavendamycin analogues that are required for their efficient reduction by NQO1 and the
selective toxicity of these analogues toward human colon adenocarcinoma NQO1-rich
BE-NQ cells compared to NQO1-deficient BE cells. In addition, there is currently no
information on how electrochemical characteristics of lavendamycin analogues correlate
with their substrate specificities for NQO1. Therefore, we also sought to determine the
electrochemical ease of reduction of the lavendamycin analogues and to examine how the
electronic features of these compounds impact their rate of reduction by NQO1.

2.3

Materials and Methods
2.3.1 Chemistry. Our studies have been possible through the success of Dr.

Mohammad Behforouz’s laboratory in developing short and efficient syntheses for a
variety of variously substituted lavendamycin analogues (Chart 2.1) possessing the full
pentacyclic structure. General Methods are described in the 2003 and 2005 papers by
Behforouz et al. and Hassani et al.44,45
2.3.2 Electrochemistry. Cyclic voltammetry (CV) for lavendamycin analogues
was conducted using a BAS CV-50W electrochemical analyzer equipped with a standard
three-electrode cell. This cell was designed to allow the tip of the reference electrode to
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approach closely to the working electrode. Voltammetric experiments were performed
using Ag/AgCl as the reference electrode, a glossy carbon (GC) rod as the working
electrode and a platinum (Pt) wire as the auxiliary electrode. Potential data are referred
to the Ferrocene (0/+) couple, which is oxidized in dried dimethylsulfoxide (DMSO) at
+0.52 V vs. Ag/AgCl. Positive-feedback iR compensation was routinely applied. The
working electrode was regularly polished using alumina. Typically, a solution containing
1 mM of the lavendamycin analogues and 0.1 M supporting electrolyte,
tetrabutylammonium hexafluorophosphate (Bu4NPF6), was prepared using dried DMSO.
All samples were purged with argon prior to use and kept under a continuous flow of
argon during the course of the experiments. All CV data were recorded at a potential
range between 0.00 and -2.00 V and at potential sweep rates of 50 to 500 mV/s. All
measurements were performed at 22 ± 1 °C.
2.3.3 Cell Culture. BE human colon adenocarcinoma cells and stably NQO1transfected BE-NQ cells46 were a gift from Dr. David Ross (University of Colorado
Health Sciences Center, Denver, CO). Cells were grown in a minimum essential medium
(MEM) with Earle’s salts, non-essential amino acids, L-glutamine and
penicillin/streptomycin, and supplemented with 10% fetal bovine serum (FBS), sodium
bicarbonate and HEPES. Cell culture medium and supplements were obtained from
Gibco, Invitrogen Co., Grand Island, NY. The cells were incubated at 37°C under a
humidified atmosphere containing 5% CO2.
2.3.4 Cytochrome c Assay. Lavendamycin analogue reduction was monitored
using a spectrophotometric assay in which the rate of reduction of cytochrome c was
quantified at 550 nm. Briefly, the assay mixture contained cytochrome c (70 µM),
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NADH (1 mM), human recombinant NQO1 (0.1-3 µg) (gift from Dr. David Ross,
University of Colorado Health Sciences Center, Denver, CO) and lavendamycins (25
µM) in a final volume of 1 mL Tris-HCl (25 mM, pH 7.4) containing 0.7 mg/mL BSA
and 0.1% Tween-20. Reactions were carried out at room temperature and started by the
addition of NADH. Rates of reduction were calculated from the initial linear part of the
reaction curve (0-30 s), and results were expressed in terms of µmol of cytochrome c
reduced/min/mg of NQO1 using a molar extinction coefficient of 21.1 mM-1 cm-1 for
cytochrome c. All reactions were carried out at least in triplicate.
2.3.5 MTT Assay. Growth inhibition was determined using the MTT
colorimetric assay. Cells were plated in 96-well plates at a density of 10,000 cells/mL
and allowed to attach overnight (16 h). Lavendamycin analogue solutions were applied
in medium for 2 hours. Lavendamycin analogue solutions were removed and replaced
with fresh medium, and the plates were incubated at 37 °C under a humidified
atmosphere containing 5% CO2 for 4-5 days. MTT (50 µg) was added and the cells were
incubated for another 4 hours. Medium/MTT solutions were removed carefully by
aspiration, the MTT formazan crystals were dissolved in 100 µL DMSO, and absorbance
was determined on a plate reader at 560 nm. IC50 values (concentration at which cell
survival equals 50% of control) were determined from semi-log plots of percent of
control vs. concentration. Selectivity ratios were defined as the IC50 value for the BE cell
line divided by the IC50 value for the BE-NQ cell line.
2.3.6 Clonogenic Assay. Cells were harvested from logarithmic-phase growing
cultures and plated at densities of 1000 cells per 100-mm dish to yield a readily
quantifiable number of colonies at the end of the experiment. After 24 hours, cells were
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treated with lavendamycin analogues, 2% DMSO (drug vehicle) or no treatment (control)
for 2 hours at 37 °C. After 2 hours, drug-containing medium was replaced with fresh
drug-free medium. Cells were incubated at 37 °C under a humidified atmosphere
containing 5% CO2 for 12 days. Then, the medium was removed and colonies were
washed twice with PBS, fixed and stained with 0.1% (w/v) Coomassie Blue dye in 30%
methanol and 10% acetic acid for 1-2 minutes. Surviving colonies (> 50 cells) were
counted and the surviving fraction determined by dividing the number of colonies in a
treatment dish by the number of colonies in the control dish. IC50 values (concentration
at which cell survival equals 50% of control) were determined from semi-log plots of
percent of control vs. concentration. Selectivity ratios were defined as the IC50 value for
the BE cell line divided by the IC50 value for the BE-NQ cell line.

2.4

Results and Discussion
2.4.1 Electrochemistry. The aim of the electrochemical studies was to

determine the relative ease of reduction of the lavendamycin analogues and to investigate
how the electrochemical behavior of these compounds correlates with their reduction rate
by NQO1. Electrochemical studies of a number of lavendamycin analogues were carried
out. In these studies, dried DMSO and Bu4NPF6 were used as solvent and the supporting
electrolyte, respectively. Cathodic and anodic peak potentials, Epc and Epa, respectively,
were measured and the midpoint of the peak potentials was used to determine E1/2 values,
E1/2 = (Epc + Epa)/2. E1/2 values were consistent for the potential sweep rates in the range
of 50 to 500 mV/s. The E1/2 values determined from the recorded voltammograms at the
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potential sweep rates of 50, 100, 200, 400 and 500 mV/s were averaged and reported with
reference to Ferrocene (Fc0/+) E1/2 value (Table 2.1).
All of the lavendamycin analogues exhibited reversible electrochemistry. The
analogues with electron-withdrawing groups at the R1 position showed similar E1/2 values,
between -0.85 and -0.99 V, with the exception of compound MB-361 that exhibited a
slightly more negative E1/2 value (-1.13), which can be in part due to the presence of an
electron-donating group at the R2 position (Table 2.1). The lavendamycin analogues with
electron-donating groups at the R1 position showed slightly more negative E1/2 values,
between -1.01 and -1.09 V, compared to the former group (Table 2.1). In general, the
lavendamycin analogues with electron-withdrawing groups at the R1 position were easier
to reduce electrochemically compared to the ones with electron-donating groups at this
position (Table 2.1).
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Table 2.1. Electrochemical reduction potentialsa (in DMSO) of lavendamycin analogues
(MB) versus Ferrocene.
O
R2
R1

N

N
O
HN

MB

R1

R3
R4

R2

R3

R4

Epc

Epa

E1/2 (V)

(V)

(V)

vs Fc

65

CH3CONH

H

H

H

-0.95

-0.95

-0.95

47

CH3CONH

H

CO2CH3

H

-0.92

-0.83

-0.88

361

CH3CONH

N(CH2)4

CO2CH3

CH3

-1.16

-1.10

-1.13

362

CH3CONH

N(CH2)2

CONH2

H

-0.99

-0.93

-0.96

21

CH3CONH

H

CO2CH3

CH3

-0.91

-0.85

-0.88

320

CH3CONH

H

CO2(CH2)2OH

H

-1.02

-0.95

-0.99

76

CH3CONH

H

CONH2

H

-0.88

-0.82

-0.85

323

n-C3H7CONH

H

CONH2

H

-0.92

-0.89

-0.91

328

NH2

Cl

CO2CH3

CH3

-1.01

-1.01

-1.01

55

22

NH2

H

CO2CH3

CH3

-1.10

-1.04

-1.07

97

NH2

H

CONH2

H

-1.09

-1.05

-1.07

353

NH2

H

CH2OH

H

-1.11

-1.06

-1.09

348

NH2

H

H

H

-1.12

-1.06

-1.09

355

H

H

H

H

-0.88

-0.85

-0.87

(CH2) 4N = N

a

(CH2)2N = N

E1/2 values (± 0.005V) calculated as (Epc+ Epa)/2 are averages of the values determined

from voltammograms recorded at potential sweep rates of 50, 100, 200, 300, 400 and 500
mV/s; Epc = Cathodic peak potential; Epa = Anodic peak potential.
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Although all of the investigated lavendamycin analogues possessed similar E1/2
values (-0.85 to -1.13 V) (Table 2.1), the rate of reduction of these compounds by NQO1
differed dramatically (Table 2.2). Compounds MB-22, -97, -348 and -353 were among
the good substrates for NQO1 (high rate of reduction by NQO1) (Table 2.2), but they
exhibited the most negative E1/2 values and were among the most difficult to reduce
electrochemically (Table 2.1). This suggests that their substituent size and potential
ability to form efficient interactions such as hydrogen bonds inside the active site of the
enzyme may play a more important role than the electrochemical reduction potentials in
their substrate specificity (See Chapter 3). Although, compound MB-323 possessed an
E1/2 value that is in the higher range of the observed E1/2 values (-0.91) (Table 2.1), it
displayed very poor substrate specificity for NQO1 (Table 2.2). This also indicates that
other factors such as lavendamycin substituent size, steric influence and lack of formation
of efficient interactions in the NQO1 active site may be more important than the
electronic effects to determine the reduction efficiency of these compounds by NQO1
(See Chapter 3). In general, when the electrochemical reduction potential and rate of
reduction of the lavendamycin analogues by NQO1 were compared, no overall linear
correlation between the two factors was found (r2 = 0.029, P = 0.578) (Figure 2.1). These
findings imply that the reduction potentials of the lavendamycin analogues do not play a
major role in determination of substrate specificity of these analogues for NQO1.
Electrochemical studies can be used to determine the ease of reduction of
compounds, but there is often no overall or very small association between the rate of
reductions by NQO1 and reduction potentials for quinones such as indolequinones38,42,47
and quinolinequinones48 as previously reported. In addition, Fourie et al. suggested the
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more important role of steric effects of the functional groups of a series of benzoquinone
mustard analogues rather than electronic effects on the reduction efficiency of these
compounds by NQO1.36,49 The lavendamycin analogues exhibited similar reduction
potential values to the quinolinequinone compounds studied by Fryatt et al.48 Also, they
were easier to reduce (E1/2 values = -0.85 to -1.13 V) than the indolequinones previously
studied by Beall et al. and Swann et al. (E1/2 values = -1.19 to -1.61 V).38,42
2.4.2 Metabolism and Structure-activity Relationship (SAR) Studies.
Metabolism of the novel lavendamycin analogues by recombinant human NQO1 was
examined. The effect of functional group changes on reduction efficiency and rate of
reduction by NQO1 was studied using a spectrophotometic assay that employs
cytochrome c as the terminal electron acceptor37 and gives initial rates of lavendamycin
analogues reduction (Table 2.2). The initial reduction rates (µmol cytochrome c
reduced/min/mg NQO1) were calculated from the linear portion (0-30 s) of the reaction
graphs.
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Table 2.2. Metabolism of lavendamycin analogues (MB) by recombinant human NQO1
monitored by spectrophotometric cytochrome c assay.
O
R2
R1

N

N
O
HN

MB

R1

R3
R4

R2

R3

R4

Metabolism by
NQO1
(µmol/min/mg)
(Cytochrome c
Reduction)

65

CH3CONH

H

H

H

2.7 ± 1.2

47

CH3CONH

H

CO2CH3

H

0.9 ± 0.2

302

CH3CONH

H

CO2C4H9-n

H

8.6 ± 2.6

303

CH3CONH

H

CO2C5H11-n

H

9.2 ± 6.6

50

CH3CONH

H

CO2C5H11-i

H

35.4 ± 6.9

304

CH3CONH

H

CO2C6H13-n

H

11.7 ± 5.3

120

CH3CONH

H

CON(CH2)5

H

15.2 ± 11.5

59

118

CH3CONH

H

CON[(CH2)2O(CH2)2]

H

7.5 ± 1.5

69

ClCH2CONH

H

CO2C5H11-i

H

9.9 ± 5.6

361

CH3CONH

N(CH2)4

CO2CH3

CH3

1±1

362

CH3CONH

N(CH2)2

CONH2

H

0.2 ± 0.2

21

CH3CONH

H

CO2CH3

CH3

1.9 ± 1.7

51

CH3CONH

H

CO2C8H17-n

H

1.5 ± 0.8

320

CH3CONH

H

CO2(CH2)2OH

H

11.0 ± 2.5

344

CH3CONH

H

CO2(CH2)2OPO3H2

H

15.4 ± 0.9

76

CH3CONH

H

CONH2

H

33 ± 12

323

n-C3H7CONH

H

CONH2

H

0.1 ± 0.1

328

NH2

Cl

CO2CH3

CH3

0.9 ± 0.8

22

NH2

H

CO2CH3

CH3

21 ± 12

366

Br

H

CO2CH3

CH3

0.7 ± 0.3

83

NH2

H

CO2C8H17-n

H

106 ± 15

97

NH2

H

CONH2

H

18.3 ± 13.6

353

NH2

H

CH2OH

H

263 ± 30

60

348

NH2

H

H

H

24.0 ± 6.5

355

H

H

H

H

3.4 ± 1.2

CON(CH2 )5 = CON

(CH2) 4N = N

CON[(CH2)2O(CH2)2] = CON

(CH2)2N = N
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O

Figure 2.1. Correlation of the reduction potential values and rate of reduction of
lavendamycin analogues by NQO1.
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Figure 2.1. Correlation of the reduction potential values and rate of reduction of
lavendamycin analogues by NQO1. The reduction potential values of lavendamycin
analogues were plotted along the horizontal axis and rates of reduction of lavendamycin
analogues by NQO1 were plotted along the vertical axis. r2 = 0.029 (P = 0.578).
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Our SAR studies determined that large substituents at the quinolinedione-7position (R1) of the lavendamycin analogues were poorly tolerated and greatly reduced
the metabolism rate of the analogues by NQO1 compared to smaller substituents (MB-97
vs. MB-323, MB-50 vs. MB-69, MB-51 vs. MB-83 and MB-76 vs. MB-323) (Table 2.2).
Large substituents such as NHCOC3H7-n in MB-323 at the 7-position had the most
negative impact on the rate of reduction by NQO1 whereas NH2 followed by the
NHCOCH3 group were the best substituents for this position (Table 2.2). This could
partly be due to steric hindrance between the quinolinedione moiety (5,8- dione ring
enters the active site first) and NQO1 active site that results in unfavorable positioning of
the lavendamycin analogues for hydride ion reception from FADH2 and quinone
reduction. Our molecular modeling studies have also demonstrated that placing a small
substituent at the R1 position that is capable of hydrogen bonding with key residues of the
active site could be a contributing factor to substrate specificity of these analogues (See
Chapter 3). Faig et al. determined that positions of RH1, 2,5-diaziridinyl-3(hydroxymethyl)-6-methyl-1,4-benzoquinone,50 that point to the inner part of the NQO1
active site could accommodate only small substituents.51 Furthermore, 1,4naphthoquinones with small substituents such as an aziridine ring or CH3 at C2 and no
substituents at C3 were reported to be good substrates for NQO1.52
Dipyrroloimidazobenzimidazole compounds with both pyrrolo rings bearing bulky
substituents were determined to be poor substrates for NQO1 due to steric interactions
with residues of the NQO1 active site.53
Comparison of analogues MB-328 vs. MB-22 and MB-362 vs. MB-76 determined
that 6-unsubstituted (R2) lavendamycin analogues are far better substrates for NQO1 than
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the corresponding 6-substituted counterparts (Table 2.2). This is likely due to active site
constraints and steric effects caused by substituents that hinder entrance or proper
positioning of the 5,8-dione moiety of the analogues toward the key residues of the active
site and the FAD isoalloxazine ring for hydride ion reception and quinone reduction.
This finding is consistent with other studies that previously showed that increased
bulkiness of the substituents at C5 position on EO9, 3-hydroxy-5-aziridinyl-1-methyl-2(1H-indole-4,7-dione)-propenol,54 dramatically reduced rates of reduction by NQO1.37,51
Another study determined that indolequinones and mitosenes with bulky amine
substituents at C5 and C7 positions, respectively, are not substrates for NQO1 due to
steric effects.38
A number of substituents at the 2'-position of the fused indolopyridine moiety
(R3) were also investigated. Among the analogues that shared an NH2 group at the R1
position and had no substituent at R2, 2'-CH2OH derivative (MB-353) was the best
substrate followed by the 2'-CO2C8H17-n derivative (MB-83) (Table 2.2). Also, our
molecular modeling studies have demonstrated that the CH2OH group at R3 was capable
of hydrogen bond formation with the key residues of the NQO1 active site and therefore
could be an important contributing factor to substrate specificity (See Chapter 3). A
CH2OH group at the C6 position of a series of substituted 1,4-naphthoquinones also
contributed the most to substrate specificity for NQO1.52 Phillips et al. determined that
some of the good indolequinone substrates for NQO1 including EO9 possessed a CH2OH
group at the analogous C3 position.37 Furthermore, RH1, which is an excellent substrate
for NQO1, possesses a CH2OH group at C3 position.8,50
2.4.3 In Vitro Cytotoxicity. Cytotoxicity studies were also performed on
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representative lavendamycin analogues with cell survival being determined by the
colorimetric MTT and clonogenic assays. We used the BE human colon adenocarcinoma
cells stably transfected with human NQO1 cDNA.50 The BE cells had no measurable
NQO1 activity whereas activity in the transfected cells (BE-NQ) was greater than 660
nmol/min/mg total cell protein using dichlorophenolindophenol (DCPIP) as the standard
electron acceptor. We also evaluated the correlation between the chemosensitivity results
of clonogenic and MTT assays in both cell lines for three lavendamycin analogues, MB22, MB-323 and MB-353. There was an excellent positive linear correlation between the
IC50 values of the two assays for the three lavendamycins for BE (r2 = 0.999, P = 0.03),
BE-NQ (r2 = 0.999, P = 0.025) and both cell lines (r2 = 0.990, P = 0.0001) (Figure 2.2).
In this study the cytotoxicity of representative lavendamycin analogues (Table 2.3) has
been compared using these cell lines.
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Figure 2.2. Correlation of the mean IC50 values obtained by MTT and clonogenic
assays.
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Figure 2.2. Correlation of the mean IC50 values obtained by MTT and clonogenic
assays. The mean IC50 values obtained by MTT assay were plotted along the horizontal
axis and mean IC50 values obtained by clonogenic assay were plotted along the vertical
axis. r2 = 0.990 (P = 0.0001).
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Table 2.3. Cytotoxicity of lavendamycin analogues (MB) towards BE (NQO1-deficient)
and BE-NQ (NQO1-rich) human colon adenocarcinoma cell lines.
O
R2
R1

N

N
O
HN

MB

R1

R3
R4

R2

R3

R4

Cytotoxicity IC50 (µM)

Selectivity
Ratio
[IC50 (BE-

BE-NQ

BE

WT) / IC50
(BE-NQ)]

302

CH3CONH

H

CO2C4H9-n

H

20.5 ± 0.6

20.0 ± 2.3

1.0

21

CH3CONH

H

CO2CH3

CH3

13.2 ± 0.7

19.3 ± 4.3

1.5

51

CH3CONH

H

CO2C8H17-n

H

>50

>50

-

344

CH3CONH

H

CO2(CH2)2OPO3H2

H

6.8 ± 0.6

8.1 ± 0.5

1.2

76

CH3CONH

H

CONH2

H

0.8 ± 0.0

3.5 ± 0.7

4.4

323

n-C3H7CONH

H

CONH2

H

21.4 ± 1.2

>50

2.3

22

NH2

H

CO2CH3

CH3

0.5 ± 0.1

4.7 ± 0.7

9.4

366

Br

H

CO2CH3

CH3

>50

>50

-

83

NH2

H

CO2C8H17-n
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H

H

H

H

12.4 ± 1.0

9.3 ± 1.2

0.8
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Lavendamycin analogues such as MB-22, -76, -83, -97 and -353 that were good
substrates for NQO1 (Table 2.2) were also more toxic to the NQO1-rich BE-NQ cell line
than the NQO1-deficient BE cell line (Table 2.3). Compound MB-353, the best substrate
for NQO1 (Table 2.2), had the greatest differential toxicity with a selectivity ratio [IC50
(BE) / IC50 (BE-NQ)] of 11 (Table 2.3). Antitumor and antiproliferative activity of
lavendamycin against implanted leukemia cells in BDF1 mice and three other cancer cell
lines has been previously reported.27,55 A recent study investigating cytotoxic activities
of a series of lavendamycin analogues against A549 human lung carcinoma cells
indicated that compounds with an amide or amine substituent at the R3 position displayed
the most potent colony formation inhibitory effects.35 At a concentration of 10 nM, the
most potent compound of this group, MB-97, reduced the colony outgrowth of A549
cells by 70%.35 Since MB-97 also displayed promising cytotoxic and antitumor activities
in the National Cancer Institute’s (NCI) 60-cell line panel and in vivo hollow fiber
tumorigenesis assay, it has been considered for in vivo testing against tumor xenografts in
mice.35 Our study also determined that lavendamycin analogue MB-97 showed highly
selective toxicity toward BE-NQ cells (selectivity ratio = 9).
Lavendamycin analogues such as MB-21, -51, -323, -366 and -355 that were poor
substrates for NQO1 demonstrated no selective toxicity toward BE-NQ cells or had no
measurable cytotoxicity (IC50 > 50 µM) (Table 2.3). Although compound MB-348 was a
rather good substrate for NQO1, it displayed only minimal selective toxicity toward BENQ cells. This could be due to the less toxic nature of MB-348 (high IC50 values for both
cell lines) compared to other good substrates such as MB-76, -22 and -97 that have lower
IC50 values (Table 2.3). Overall, our results determined that the best lavendamycin
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substrates for NQO1 were also the most selectively toxic to the high NQO1 BE-NQ cell
line.

2.5

Conclusions

Large substituents at the quinolinedione-7-position (R1) of the lavendamycin
analogues were poorly tolerated and greatly decreased the rate of reduction of the
analogues by NQO1. Absence of substituents at the quinolinedione-6-position (R2) was
highly preferred. Small or large substituents were well tolerated at the 2'-position of the
fused indolopyridine moiety (R3). Addition of an NH2 group at R1 and CH2OH or
CO2C8H17-n groups at the R3 position had the greatest positive impact on substrate
specificity compared to other substituents at these positions. The best substrate was the
2'-CH2OH-7-NH2 derivative (MB-353) with a reduction rate of 263 ± 30 µmol/min/mg
NQO1 and selectivity ratio of 11. The best lavendamycin substrates for NQO1 were also
the most selectively toxic to the NQO1-rich BE-NQ cell line compared to NQO1deficient BE cells. Lavendamycin substituent size and steric influence compared to
electronic effects had a greater impact on determination of the reduction efficiency of the
compounds by NQO1. These SAR findings greatly enhance our understanding of the
required structural features for lavendamycin analogue substrate specificity for NQO1.
Performance of molecular docking studies will assist us to better understand and explain
the observed SAR data. These studies can be used for the purpose of structure-based
design of novel lavendamycin agents with improved NQO1 substrate specificity.
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Chapter 3
Development of an In Silico Model of the NAD(P)H:Quinone Oxidoreductase 1
(NQO1) Active Site and Computational Molecular Docking Studies on
Lavendamycin Antitumor Agents

3.1

Abstract

To facilitate NAD(P)H:quinone oxidoreductase 1 (NQO1)-directed lavendamycin
antitumor agent development and perform corresponding docking studies, our laboratory
developed a 1H69 crystal structure-based in silico (computer-generated) model of the
NQO1 active site. The coordinates of the crystal structure of the NQO1 complex with the
indolequinone ARH019 obtained from the Protein Data Bank (PDB ID code: 1H69) was
used as a reference structure. In order to develop the in silico model, the energyminimized compound MB-353 was superposed to the coordinates of the original
reference ligand ARH019. FAD was introduced to the active site of NQO1 as a
heteroatom file. Computational molecular docking studies were performed on two
lavendamycin analogues, MB-353 and MB-323, good and poor substrates for NQO1,
respectively. The molecular docking was performed using the FlexX module of SYBYL
6.9.1 software suite. FlexX used MB-353 as the reference ligand for docking
experiments. The docked conformations (poses) of ligands were evaluated using the
CSCORE module in SYBYL. Geometric post-docking analyses that determine
hydrogen-bonding interactions of the ligands with the key residues of the active site and
FAD and hydride ion transfer from the flavin to the ligands were performed. Of thirty
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possible docked poses of MB-353, nineteen had CSCORE ≥ 4 indicating that this ligand
was a good substrate. All of the nineteen poses were capable of forming effective
hydrogen-bonding interactions and hydride ion transfer. However, none of the MB-323
poses had a CSCORE = 5 nor was capable of hydrogen bond formation and hydride ion
transfer. Molecular docking supported a model in which the good (MB-353) versus poor
NQO1 substrate (MB-323) was capable of effective hydrogen-bonding interactions with
FAD and the key amino acid residues of the active site along with hydride ion reception.

3.2

Introduction

Molecular docking was first introduced in the early 1980s and since then has
become a useful tool and a principal component in the field of drug development and
discovery.1,2 Protein-ligand docking as a subcategory of the general field of molecular
docking has received enormous attention from the scientific community due to its
application in many fields of research including medicinal chemistry and cancer
studies.1,3 This approach has emerged as a powerful tool in the design of selective
substrates for validated targets in cancer therapy.3
Molecular docking is defined as computational methods that predict binding
orientations of ligands in the active site of the target.4-6 This approach consists of
utilizing a computer program to generate an in silico model of the target based on the
available three-dimentional (3D) crystal structure.1,2 There are two major components to
protein-ligand docking protocols including docking and scoring.1-3 Docking, which is
also known as searching/search algorithm/posing/pose prediction, is the placement of
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ligands in the target binding site. Docking makes it possible to search for and correctly
predict the ligand conformations and binding orientations.1-3 A search algorithm should
be fast and capable of effective coverage of the relevant search space.1
The prediction of binding affinities and how well ligands bind to the protein are
performed by scoring.1,2 The scoring function should distinguish the correct binding
mode (pose) among others explored through the search algorithm , and evaluate and rank
the search results accordingly.1,3 The computed interaction energy of ligand-protein
(score) of a pose determines its final rank-ordering.2 One proper scoring approach consensus score - employs several scoring functions to rank different poses.2 For a pose
to be selected and kept based on this approach , it has to be assigned high scores by a
number of different component scoring functions.2
Molecular docking methods need to utilize three-dimensional protein structures to
investigate protein-ligand molecular recognitions and binding events.2 Today, there are
more than 35,000 structures of proteins and nucleic acids stored in the Protein Data Bank
(PDB).1 This wealth of the available three-dimensional structures of proteins and
protein-ligand structural data has highly contributed to the field of molecular docking and
subsequently to the drug development process.6
When the target binding site has been already determined, one way to perform a
ligand-protein fit search is the manual docking of the corresponding ligand into the active
site.3 However, manual docking requires a great expertise and is a very labor intensive
and time consuming practice.3 Therefore, development of a general in silico model of the
target protein active site that can be used in automatic docking processes can greatly
facilitate and accelerate these processes. Several modeling studies of NQO1-quinone
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substrates have been performed to identify key components of quinone compounds,
which confer high substrate specificity.7-10 However, there has not been any systematic
attempt to develop an in silico general model of the NQO1 active site as a predictive tool.
An active site model can be utilized for docking studies and prediction of the substrate
specificity of a series of structurally related antitumor quinone compounds.9
To facilitate NQO1-directed lavendamycin antitumor agent development, we
developed an in silico model of the NQO1 active site. This model served to gain insights
into the details of molecular basis of lavendamycin binding events at the NQO1 active
site that would be used along with our structure-activity relationship (SAR) data for
structure-based design of novel lavendamycin substrates (See Chapter 4). Development
of this model will also enable rapid docking of a large number of lavendamycin
substrates into the NQO1 active site without bearing the extra effort and expense of
synthesizing and testing all the analogues. This will provide a useful tool, which is
capable of accurate prediction of the best potential lavendamycin substrates for NQO1
with high preferential toxicity towards cancer cells that overexpress this enzyme.

3.3

Materials and Methods

3.3.1 Coordinates Preparation. The coordinates of the crystal structure of
human NQO1 complex with bound FAD and the indolequinone ARH019, 3(Hydroxymethyl)-5-(2-methylaziridin-1-yl)-1-methyl-2-phenylindole-4,7-dione,11 were
obtained from the Protein Data Bank (PDB ID code: 1H6912). This structure was used as
a reference structure for the docking experiments and compound ARH019 served as the
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original reference ligand. The physiological dimer in the crystal unit was used for
docking purposes.
3.3.2 Development of In Silico Model of the NQO1 Active Site. The
molecular modeling studies were performed using SYBYL 6.9.1 software suite13 (Tripos,
Inc.; St. Louis, MO). The coordinates of the crystal structure of human NQO1 complex
with bound FAD and ARH019, obtained from the Protein Data Bank (PDB ID code:
1H6912), were utilized to develop the in silico model of the NQO1 active site.14 In order
to develop the model, the energy-minimized compound MB-353 was superposed to the
coordinates of the original reference ligand ARH019 such that overlap was optimal.
Ligand MB-353 was again energy minimized in the context of the active site and
therefore the position of the ligand within the pocket was considered optimized for the
purpose of this study. The active site was then defined as all the amino acid residues
confined within 6.5 Å radius sphere centered on the superposed ligand MB-353. The
coordinates were locally minimized and subjected to energy minimization with minimal
iterations (100) by Powell minimization standard method using Minimize Subset option
within SYBYL. This option automatically selected 24 seed amino acid residues
surrounding the superposed ligand MB-353 to perform the local minimization. Default
parameters and values within the minimization dialog were used except where otherwise
mentioned. This procedure yielded a weighted root-mean-square distance of 0.26 Å
between the 24 corresponding non-minimized and minimized residues in the structures.
The file of the composite structure containing ligand MB-353 and FAD was saved. The
composite structure without MB-353 utilized as the in silico model of the NQO1 active
site for docking studies. Ligand MB-353 served as the reference ligand for the docking

86

studies. Docking calculations were performed using one of the two identical active sites.
3.3.3 Ligand Preparation. The structures of ligands were sketched and
prepared as MOL2 files employing the Sketch Molecule module of SYBYL 6.9.1
software suite13 (Tripos, Inc.; St. Louis, MO). Initially sketched Ligands were subjected
to energy minimization (10,000 iterations) by Powell minimization standard method.
Initial Optimization and Termination parameters were set to None and Energy Change
options, respectively. Default parameters and values within the minimization dialog
(Minimize Details) were used except where otherwise noted. The final ligand
conformational coordinates were stored as MOL2 files within the database.
3.3.4 Docking. Flexible docking was performed using the FlexX module of
SYBYL 6.9.1 software suite.13 FlexX is an automatic docking program for
conformationaly flexible ligands that employs the 3D structure of the target protein in
PDB format, and is capable of determining 30 possible conformations for each docked
ligand. The final rank order of the conformations is based on the free binding energy.
This program automatically selects the base fragment of a ligand (the ligand core). The
base fragment is then placed into the active site of the target protein using the algorithmic
approach called pose clustering that is based upon a pattern recognition paradigm.
Subsequent incremental reconstruction of the complete ligand molecule is then performed
by linking the remaining components.15,16 For the in silico model, the active site was
defined as all the amino acid residues confined within 6.5 Å radius sphere centered on the
superposed ligand MB-353. FAD was introduced to the active site as a heteroatom file in
MOL2 format.
3.3.5 Scoring Functions. The docked conformations of ligands were evaluated
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and ranked using FlexX and four scoring functions implemented in the CSCORE module
in SYBYL. CSCORE is a consensus scoring program that integrates multiple wellknown scoring functions such as FlexX, ChemScore,17 D-Score,18 G-Score19 and PMFScore20 to evaluate docked conformations. Individual scoring functions are used to
predict the affinity of the ligand binding to a target protein. CSCORE creates columns in
a molecular spreadsheet that contains raw scores for each individual scoring function.
The consensus column contains integers that range from 0 to 5; where 5 is the best fit to
the model. Docked conformations whose scores exceed the threshold for a particular
function contribute one to the value of the consensus, whereas those with scores below
the threshold add a zero.
3.3.6 Molecular Graphics System. The molecular graphics images and surface
representations were prepared with PyMOL molecular graphics system version
PyMOLX11Hybrid 0.9721 (Delano Scientific, San Carlos, CA, USA). The data of the
coordinates of the NQO1 complex with bound FAD and docked conformations of ligands
were prepared in PDB format as PyMOL input files. PyMOL session files of the NQO1
active site with docked conformations of ligands and the superimposition of clustered
conformations were created. The images were then stored as graphic files.

3.4

Results and Discussion

3.4.1 Development of In Silico Model of the NQO1 Active Site. The
molecular modeling and docking studies were performed using SYBYL 6.9.1 software
suite13 (Tripos, Inc.; St. Louis, MO). The crystal structure of human NQO1 complex
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with bound FAD and ARH019 (Chart 3.1) (PDB ID code: 1H6912) has been suggested as
an appropriate model for molecular docking studies of other quinone compounds such as
streptonigrin (SN).12 Therefore, the coordinates of this crystal structure were used as the
reference structure to develop an in silico model of the NQO1 active site for docking
studies. To develop the in silico model that can be used in lavendamycin docking studies
we introduced a reference ligand into the active site that could be recognized by the
FlexX docking program. Since FlexX could not recognize ARH019 as the reference
ligand, compound MB-353 (Chart 3.1) was used as the reference ligand for lavendamycin
docking studies. MB-353 was superposed to the coordinates of ARH019 such that
overlap was optimal. ARH019 served as the reference of location for MB-353. The
active site was then defined as all the amino acid residues confined within 6.5 Å radius
sphere centered on the superposed ligand MB-353. The file of the composite structure
containing ligand MB-353 and FAD was saved. This composite structure without MB353 utilized as the in silico model of the NQO1 active site for automatic docking studies
(Figure 3.1). FlexX used MB-353 as the reference ligand in automatic docking processes
and FAD was introduced to the active site as a heteroatom file in MOL2 format.
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Chart 3.1. Chemical structures of the indolequinone ARH019 and lavendamycin
analogue MB-353.
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CH2OH

Figure 3.1. The developed in silico model of the NQO1 active site.
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Figure 3.1. The developed in silico model of the NQO1 active site. The coordinates of
the crystal structure of human NQO1 complex with bound FAD and ARH019 (PDB ID
code: 1H69) were utilized to develop the in silico model of the NQO1 active site. To
develop the model, the energy-minimized compound MB-353 was superposed to the
coordinates of the ligand ARH019. The active site was then defined as all the amino acid
residues confined within 6.5 Å radius sphere centered on the superposed ligand MB-353.
The composite structure containing ligand MB-353 and FAD was saved. The composite
structure without MB-353 was utilized as the in silico model of the NQO1 active site for
lavendamycin docking studies. Residues of the active site (lime) and FAD (blue) are
represented as stick models. The rest of the structure is represented as a secondary
structure cartoon. The atoms are colored: red, oxygen atoms; blue, nitrogen atoms;
orange, phosphorus atoms and white, hydrogen atoms.
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3.4.2 Docking Studies. Computational and comparative molecular docking
studies were performed on two lavendamycin analogues, MB-323 and MB-353, poor and
good substrates for NQO1, respectively. Flexible docking was performed using the
FlexX module of SYBYL that is capable of determining 30 possible poses for each
docked ligand.15,16 The docked conformations of ligands MB-323 and MB-353 were
evaluated and ranked using FlexX and four scoring functions implemented in the
CSCORE module in SYBYL. CSCORE is the consensus score computed from FlexX,
ChemScore,17 D-Score,18 G-Score19 and PMF-Score20 scoring functions, in which docked
poses are evaluated and ranked from 0 to 5; where 5 is the best fit to the model. Table
3.1 displays the number of poses of ligands MB-323 and MB-353 in each score group of
CSCORE function.

93

Table 3.1. Number of poses of ligands MB-323 and MB-353 in each score group of
CSCORE function.

Compound

MB-323

MB-353

CSCORE

0

1

2

3

4

5

0

1

2

3

4

5

Number of

18

8

-

-

4

-

3

3

1

4

15

4

Poses
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Ligand MB-353 possessed a higher number of poses with more optimal CSCORE
values compared to MB-323 (Table 3.1). To minimize the number of false positives
and/or negatives, visual screening of the binding orientations of the poses and geometric
post-docking analyses were performed. The analyses included distance measurements
and poses geometries that determined: a) hydrogen-bonding interactions of the ligand
poses with the key amino acid residues of the NQO1 active site including Tyr-126, -128,
Gly-149 and His-161, b) hydride ion transfer from the N5 of the FAD isoalloxazine ring
to the ligands at either carbonyl oxygens (O5 or O8) or at a ring carbon, and c) the angle
between the quinone-moiety plane of the ligands and the FAD isoalloxazine ring.
Residue numbers in this study are those used in the Protein Data Bank coordinates, PDB
ID code: 1H69.12
Of the thirty possible docked conformations of ligand MB-353, twenty-four poses
(CSCORE ≥ 2) displayed binding orientations similar to that of the original reference
ligand ARH019. Compound ARH019 has been shown to enter the active site by the 4,7dione moiety where the plane of the indolequinone forms a partial aromatic-ring parallel
stacking with the FAD isoalloxazine ring, and the corresponding plane-to-plane angle is
16°.12 The methyl-aziridinyl group of ARH019 stacks against the Trp-105 indole and 2phenyl group stacks over Gly-149 and Gly-150 and points toward the outside of NQO1
active site.12 The binding orientation of ARH019, and ligands MB-323 and MB-353 in
the NQO1 active site were similarly determined by the positioning of quinone carbonyl
oxygens and atoms toward the isoalloxazine ring atoms of FAD and residues of the active
site. Compound ARH019 carbonyl oxygen O4 in comparison to O7 is positioned closer
to Tyr-126, -128 and the N5 of FAD.12

95

Nineteen poses of ligand MB-353 had CSCORE ≥ 4 (Table 3.1). Poses with
CSCORE ≥ 4 fell into four clusters, where a cluster is defined as a group of poses that
gives a root mean square deviation (RMSD) less than 0.8 Å for the quinolinedione and
indolopyridine moieties atoms. Poses 1, 9 and 15 (Figure 3.2a) and 20, 24 and 27 (Figure
3.2b) fell into two clusters in which the RMS deviation of the poses equaled zero and the
difference was in the binding orientation of the CH2OH group in the NQO1 active site
(Figures 3.2a and 3.2b). Poses 3, 4, 5, 6, 7, 11 and 12 (Figure 3.2c) and 8, 10, 18, 19 and
26 (Figure 3.2d) were clustered into two groups that yielded RMS deviations of < 0.8 Å.
All of the clustered poses of MB-353 entered the active site by the 5,8-dione moiety
similar to ARH019, where the departure of the planes of most of these poses from a
complete aromatic-ring parallel stacking with the FAD isoalloxazine ring closely
resembled that of ARH019 (Figure 3.2) (Table 3.2).
The purpose of pose clustering is to determine the preferred binding orientation of
ligands.10 The carbonyl oxygen O5 of the clustered poses compared to O8 was
positioned closer to Tyr-126, -128 and the FAD N5 (Table 3.2) resembling compound
ARH019 binding orientation, suggesting that this could be the preferred binding
orientation for ligand MB-353 (Figure 3.2). Also, the departure of the planes of the most
of these poses from an exact aromatic parallel stacking with FAD closely resembled that
for the reference ligand ARH019 (Table 3.2).
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Figure 3.2. View of the superposition of the docked poses of MB-353 (CSCORE ≥ 4) in
the NQO1 active site.

a)

b)

c)

d)
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Figure 3.2. View of the superposition of the docked poses of MB-353 (CSCORE ≥ 4) in
the NQO1 active site. a) View of the superposition of the docked poses 1, 9 and 15 of
ligand MB-353 (magenta, cyan and yellow) (CSCORE = 5, 4 and 4) in the NQO1 active
site (RMSD = 0 Å). b) View of the superposition of the docked poses 20, 24 and 27 of
MB-353 (magenta, cyan and yellow) (CSCORE = 4) in the NQO1 active site (RMSD = 0
Å). c) View of the superposition of the docked poses 3, 4, 5, 6, 7, 11 and 12 of MB-353
(magenta, cyan, yellow, salmon, blue, orange and green) (CSCORE = 4) in the NQO1
active site (RMSD < 0.8 Å). d) View of the superposition of the docked poses 8, 10, 18,
19 and 26 of MB-353 (yellow, salmon, magenta, cyan and orange) (CSCORE = 5, 5, 4, 4
and 4) in the NQO1active site (RMSD < 0.8 Å). Residues of the active site (lime), FAD
(blue), and MB-353 are represented as stick models. The atoms are colored: red, oxygen
atoms; blue, nitrogen atoms and white, hydrogen atoms.
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Table 3.2. Geometric post-docking analysis, measurements and calculations of the thirty
possible poses of ligand MB-353 in the NQO1 active site.

Pa

Cb

O5

O5

O8

O8

N5

N5

N5

N5

Anglec

-

-

-

-

-

-

-

-

(º)

Tyr126

Tyr128

Tyr126

Tyr128

O5 (Å)

O8 (Å)

C6 (Å)

C7 (Å)

(Å)

(Å)

(Å)

(Å)

2

5

3.960

2.051

9.165

6.132

4.515

7.382

4.310

5.198

24.96

1

5

3.705

2.055

8.743

5.774

4.359

7.053

4.044

4.893

18.18

10

5

3.865

2.190

9.015

6.199

4.355

7.133

4.122

4.988

21.29

8

5

3.822

2.142

8.849

6.061

4.311

7.004

3.963

4.820

21.63

27

4

3.880

1.842

8.853

5.678

4.609

7.331

4.296

5.146

16.87

24

4

3.880

1.842

8.853

5.678

4.609

7.331

4.296

5.146

16.87

19

4

4.240

1.991

9.437

6.419

4.693

7.522

4.451

5.326

25.87

18

4

3.635

1.752

8.682

5.783

4.674

7.032

4.148

4.897

21.04

9

4

3.705

2.055

8.743

5.774

4.359

7.053

4.044

4.893

18.18

26

4

4.240

1.991

9.437

6.419

4.693

7.522

4.451

5.326

25.87

15

4

3.705

2.055

8.743

5.774

4.359

7.053

4.044

4.893

18.18

7

4

3.896

2.100

9.008

6.017

4.379

7.271

4.261

5.146

15.40

12

4

3.760

2.257

8.976

6.058

4.237

6.934

4.009

4.848

18.33

6

4

3.896

2.100

9.008

6.017

4.379

7.271

4.261

5.146

15.40

5

4

3.896

2.100

9.008

6.017

4.379

7.271

4.261

5.146

15.40

4

4

3.896

2.100

9.008

6.017

4.379

7.271

4.261

5.146

15.40

3

4

3.760

2.257

8.976

6.058

4.237

6.934

4.009

4.848

18.33

11

4

3.842

1.981

9.071

6.159

4.593

7.066

4.265

5.026

18.88

20

4

3.880

1.842

8.853

5.678

4.609

7.331

4.296

5.146

16.87

21

3

4.273

2.592

9.493

6.405

4.138

7.517

4.302

5.322

27.95

99

13

3

3.792

1.704

9.022

6.026

4.952

7.154

4.555

5.219

18.25

16

3

3.826

1.724

8.924

5.918

4.714

7.092

4.314

5.048

13.46

14

3

3.792

1.704

9.022

6.026

4.952

7.154

4.555

5.219

18.25

22

2

3.853

1.690

8.916

5.976

4.753

6.996

4.262

4.960

14.29

28

1

6.654

4.783

9.874

7.394

7.306

12.051

9.310

10.551

102.72

29

1

9.117

6.163

4.100

1.869

7.306

4.653

5.502

4.735

11.76

23

1

7.305

5.108

2.521

2.661

7.690

6.728

5.708

5.376

114.20

30

0

6.654

4.783

9.874

7.394

7.306

12.051

9.310

10.551

102.72

17

0

6.458

4.530

9.980

7.878

6.974

12.182

9.198

10.491

108.29

25

0

7.027

4.920

9.890

7.543

7.699

12.561

10.035

11.223

98.04

a

P = Pose

b

C = CSCORE

c

Plane-to-plane angle between the isoaloxazine ring of FAD and the quinolinequinone

moiety of ligand MB-353
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In the NQO1 active site, the hydroxyl groups of Tyr-126 and -128 and/or the N or
NH of His-161 can form hydrogen bonds with carbonyl oxygens and/or other atoms of
quinone substrates.10,12,22 One crucial determining factor of quinone substrate binding
strength in the NQO1 active site is the quinone oxygens capability of forming hydrogenbonding interactions with Tyr-126 and -128.10 The carbonyl oxygens O4 and O7 of the
quinone nucleus of ARH019 form hydrogen bonds with the OH of Tyr-126 and NH of
His-161, respectively.12 Good substrates for NQO1 such as RH1 and EO9 are capable of
forming hydrogen-bonding interactions with the key residues of the NQO1 active site.12
The carbonyl oxygens O1 and O4 of RH1 also form hydrogen bonds with the NH of His161 and the hydroxyl group of Tyr-128, respectively.12 The O4 and O7 of EO9 is
capable of hydrogen-bonding interaction formation with the Tyr-126 OH and NH of His161, respectively.12
Although all of the clustered poses of MB-353 were capable of forming
hydrogen-bonding interactions and hydride ion reception from the FAD N5, these poses
differed in the number of and ability to form hydrogen bonds with FAD and the residues
of the NQO1 active site (Table 3.2). Among the poses of ligand MB-353, poses 1 and 2
formed the highest number of hydrogen bonds in the active site of the enzyme. The 5,8dione moiety of pose 1 with CSCORE = 5 stacked over the isoalloxazine ring of FAD
and the NH2 group at the quinolinedione-7-position was placed close to His-161 (Figures
3.3a and 3.3b). The fused three-ring indolopyridine moiety pointed toward the outside of
the active site. The CH2OH group at the indolopyridine -2'-position was placed close to
Gly-149 (Figures 3.3a and 3.3b). Pose 2 (CSCORE = 5) also positioned in the NQO1
active site in a very similar way to pose 1 (Figure 3.3c) (Table 3.2). The carbonyl oxygen
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O5 of MB-353 poses 1 and 2 formed a hydrogen bond with the Tyr-128 OH and one
hydrogen atom of the NH2 substituent formed a hydrogen bond with the N of His-161
(Figures 3.3b and 3.3c). Another hydrogen atom of the NH2 substituent was capable of
forming hydrogen-binding interactions with the O2 and N3 of FAD (Figures 3.3b and
3.3c). The CH2OH group of the indolopyridine moiety further stabilized the binding by
making a hydrogen bond to the carbonyl oxygen of Gly-149 (Figures 3.3b and 3.3c).
Poses 1 and 2 of ligand MB-353 with high CSCORE of 5 made the highest number of
hydrogen-bonding interactions in the active site resulting in favorable binding orientation
for efficient hydride ion reception and quinone reduction.
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Figure 3.3. Molecular model of the poses of MB-353 (CSCORE = 5) docked into the
NQO1 active site.

a)

b)

c)
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Figure 3.3. Molecular model of the poses of MB-353 (CSCORE = 5) docked into the
NQO1 active site. a) Depiction of the molecular surface of the NQO1 active site region.
The surface of the pocket is colored lime with FAD (blue) and the docked pose 1 of MB353 (magenta) (CSCORE = 5) represented as stick models. b) Molecular model of the
pose 1 of MB-353 docked into the NQO1 active site. c) Molecular model of the pose 2
of MB-353 (CSCORE = 5) docked into the NQO1 active site. In (b) and (c) the carbonyl
oxygen O5 of MB-353 poses 1 and 2 formed a hydrogen bond with the Tyr-128 OH and
one hydrogen atom of the NH2 substituent formed a hydrogen bond with the N of His161. Another hydrogen atom of the NH2 substituent was capable of forming hydrogenbinding interactions with the O2 and N3 of FAD. The CH2OH group of the
indolopyridine moiety further stabilized the binding by making a hydrogen bond to the
carbonyl oxygen of Gly-149. In (b) and (c) residues of the active site (lime), FAD (blue),
and MB-353 (magenta) are represented as stick models and the rest of the structure is
represented as a secondary structure cartoon. The atoms are colored: red, oxygen atoms;
blue, nitrogen atoms and white, hydrogen atoms. Hydrogen bonds are represented as
yellow dashed lines.
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However, of the thirty possible docked conformations of ligand MB-323, twentysix poses possessed CSCORE ≤ 1 and no conformation had a CSCORE = 5 (Table 3.1).
None of the thirty poses had a binding orientation similar to that of the ligand ARH019.
Pose 12 with CSCORE = 4 had a binding orientation opposite that of the original
reference ligand where carbonyl oxygen O8 of pose 12 compared to O5 was positioned
closer to Tyr-126, -128 and the FAD N5 (Figure 3.4a) (Table 3.3). The quinone nucleus
partially stacked over the isoalloxazine ring of FAD and the NHCOC3H7-n group at the
quinolinedione-7-position stacked over the isoalloxazine ring of FAD (Figure 3.4a). The
fused three-ring indolopyridine moiety pointed toward the outside of the active site
(Figure 3.4a). Neither of the carbonyl oxygens O5 and O8 of pose 12 was capable of
forming hydrogen bonds with the residues of the active site unlike poses 1 and 2 of ligand
MB-353 (Figure 3.4a) (Table 3.3). The other three poses (11, 26 and 28) of MB-323 with
CSCORE = 4 entered the active site of NQO1 with the fused three-ring indolopyridine
moiety where the quinolinedione moiety pointed toward the outside of the active site
(Figures 3.4b and 3.4c) (Table 3.3). Compound ES1340, 5-Methoxy-3(phenyloxymethyl)-1,2-dimethylindole-4,7-dione,23 which is a poor substrate for NQO124
has been shown to position in the NQO1 active site such that the 4,7-dione moiety points
to the outside of the active site.25 The binding orientations of the poses of ligand MB-323
were not favorable for formation of hydrogen-bonding interactions, hydride ion reception
and quinone reduction. The remaining twenty-six poses with CSCORE of 0 or 1 did not
merit further considerations.
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Figure 3.4. Molecular model of the poses of MB-323 (CSCORE = 4) docked into the
NQO1 active site.

a)

b)

c)
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Figure 3.4. Molecular model of the poses of MB-323 (CSCORE = 4) docked into the
NQO1 active site. a) Molecular model of the pose 12 of MB-323 (CSCORE = 4) docked
into the NQO1 active site. Residues of the active site (lime), FAD (blue) and MB-323
(magenta) are represented as stick models and the rest of the structure is represented as a
secondary structure cartoon. b) Depiction of the molecular surface of the NQO1 active
site region. The surface of the pocket is colored lime with FAD (blue) and the docked
poses 11, 26 and 28 of MB-323 (magenta, yellow and cyan) (CSCORE = 4) represented
as stick models. c) Molecular model of the poses 11, 26 and 28 of MB-323 docked into
the NQO1 active site. Residues of the active site (lime), FAD (blue) and MB-323
(magenta, yellow and cyan) are represented as stick models and the rest of the structure is
represented as a secondary structure cartoon. The atoms are colored: red, oxygen atoms;
blue, nitrogen atoms and white, hydrogen atoms.
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Table 3.3. Geometric post-docking analysis, measurements and calculations of the thirty
possible poses of ligand MB-323 in the NQO1 active site.

Pa

Cb

O5

O5

O8

O8

N5

N5

N5

N5

Anglec

-

-

-

-

-

-

-

-

(º)

Tyr126

Tyr128

Tyr126

Tyr128

O5 (Å)

O8 (Å)

C6 (Å)

C7 (Å)

(Å)

(Å)

(Å)

(Å)

12

4

9.319

6.115

4.323

2.240

7.734

4.353

5.656

4.654

14.40

28

4

9.370

6.589

6.388

4.844

11.373

6.612

10.068

8.941

126.44

11

4

9.370

6.589

6.388

4.844

11.373

6.612

10.068

8.941

126.44

26

4

9.370

6.589

6.388

4.844

11.373

6.612

10.068

8.941

126.44

6

1

10.425

6.678

12.527

8.753

12.363

12.173

11.541

11.479

60.59

1

1

11.846

8.005

10.778

7.183

13.405

10.639

11.401

10.625

102.20

7

1

11.071

7.388

11.834

8.090

13.141

11.655

11.761

11.346

74.51

2

1

11.908

8.587

11.246

7.419

14.621

11.760

12.892

12.120

76.63

8

1

11.923

8.076

10.816

7.209

13.458

10.666

11.461

10.680

14.40

3

1

13.915

10.623

11.791

7.979

16.582

12.726

14.711

13.699

88.98

4

1

11.170

7.359

10.354

6.787

12.889

10.205

10.834

10.072

100.03

5

1

11.170

7.359

10.354

6.787

12.889

10.205

10.834

10.072

100.03

14

0

11.447

7.608

10.606

7.033

13.048

10.448

11.055

10.320

100.79

15

0

11.071

7.388

11.834

8.090

13.141

11.655

11.761

11.346

74.51

9

0

10.165

6.251

13.341

9.635

11.525

12.845

11.364

11.705

52.13

16

0

10.425

6.678

12.527

8.753

12.363

12.173

11.541

11.479

60.59

30

0

11.337

7.502

10.537

6.955

12.963

10.324

10.955

10.209

99.90

17

0

10.871

7.155

11.727

8.000

12.878

11.491

11.508

11.119

74.88

18

0

11.173

7.319

10.679

7.120

12.740

10.390

10.811

10.143

98.05

19

0

12.336

8.994

11.705

7.877

14.986

12.213

13.341

12.597

76.96
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20

0

10.165

6.251

13.341

9.635

11.525

12.845

11.364

11.705

52.13

21

0

13.563

10.281

11.495

7.696

16.260

12.419

14.341

13.329

87.30

22

0

10.165

6.251

13.341

9.635

11.525

12.845

11.364

11.705

52.13

23

0

11.071

7.388

11.834

8.090

13.141

11.655

11.761

11.346

74.51

24

0

11.739

7.899

10.741

7.147

13.314

10.592

11.320

10.556

101.46

25

0

10.165

6.251

13.341

9.635

11.525

12.845

11.364

11.705

52.13

10

0

11.189

7.511

11.583

7.840

13.268

11.425

11.750

11.237

78.19

27

0

10.988

7.331

11.648

7.940

13.110

11.514

11.640

11.193

76.02

13

0

11.897

8.049

10.812

7.209

13.430

10.658

11.436

10.661

102.26

29

0

12.218

8.847

11.761

7.939

14.825

12.200

13.213

12.507

76.35

a

P = Pose

b

C = CSCORE

c

Plane-to-plane angle between the isoaloxazine ring of FAD and the quinolinequinone

moiety of ligand MB-323

109

3.5

Conclusions

The developed in silico model served to gain insights into the details of molecular
basis of lavendamycin binding events in the NQO1 active site. The molecular modeling
and docking studies demonstrated that ligand MB-353 possessed an increased number of
possible poses with favorable binding orientations to promote hydrogen bonding
interactions, hydride ion reception and quinone reduction compared to ligand MB-323.
Ligand MB-353 due to the small hydrogen bond-forming substituents possessed
structural characteristics for favorable positioning in the NQO1 active site for reduction.
Conversely, the unfavorable structural characteristics of ligand MB-323 excluded it from
proper positioning in the NQO1 active site for reduction. These findings suggest that
active site positioning contributes to the much greater substrate specificity observed for
ligand MB-353 compared to ligand MB-323. The docking studies greatly contributed to
understanding of our structure-activity relationship (SAR) data and the observed different
substrate specificity of the ligands. The use of molecular modeling and docking
techniques can contribute to future structure-based design of good NQO1 substrates for
NQO1-directed lavendamycin antitumor agent development. Therefore, the data
obtained from the molecular docking in conjunction with the SAR studies will be utilized
for the structure-based design of novel improved lavendamycin substrates for NQO1.
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Chapter 4
Lavendamycin Antitumor Agents: Structure-based Design, Validation of In Silico
Model of the NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Active Site, and
Molecular Docking and Biological Studies

4.1

Abstract

A 1H69 crystal structure-based in silico model of the NAD(P)H:quinone
oxidoreductase 1 (NQO1) active site has been developed in our laboratory to facilitate
NQO1-directed lavendamycin antitumor agent development. Lavendamycin analogues
were designed as NQO1 substrates utilizing our structure-activity relationship (SAR) and
molecular docking data as structure-based design criteria. Docking studies of the
designed analogues were performed using the in silico model to predict their NQO1
substrate specificity. The molecular docking was performed using the FlexX module of
SYBYL 7.0 software suite. Metabolism and cytotoxicity studies on the analogues with
recombinant human NQO1 and human colon adenocarcinoma cells (NQO1-deficient BE
and NQO1-rich BE-NQ) were also performed. Docking and biological data were
consistent suggesting that there was an excellent association between the docking and
biological data. Analogues MB-116, -340, -100, -137 and -73 with reduction rates of 143
± 11, 60 ± 8, 7.0 ± 1.5, 4.9 ± 2.9 and 3.4 ± 1.7 µmol/min/mg NQO1 were categorized as
good, good, poor, poor and poor NQO1 substrates, respectively, by docking and
metabolism data. Analogues MB-116, -340 and -100 exhibited selectivity ratios [IC50
(BE) / IC50 (BE-NQ)] of 30, 7 and 1, respectively, while no measurable cytotoxicity for
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MB-137 and -73 was found. Overall, our results suggest practicality of the design criteria
resulting in the discovery of two good NQO1 substrates with high selectivity ratios. The
observed consistency between the docking and biological data determines that the in
silico model of the NQO1 active site possesses practical predictive power. Therefore,
this model can be utilized as a cost- and time-efficient tool to facilitate and accelerate
NQO1-directed lavendamycin antitumor agent development. The acquired docking data
can further be used for future structure-based design of lavendamycins to result in
discovery of optimized ligands as potential novel bioreductive drugs.

4.2

Introduction

Bioreductive enzyme-directed antitumor agent development depends on
identification of chemotherapeutic agents with high substrate specificity for target
reductases.1 Structure-based ligand design is an efficient approach in modern drug
development for targets with resolved three-dimensional (3D) structures.2-4 This field
was evolved more than two decades ago as an approach to take advantage of the
increasing number of protein crystal structures being added to the database.5 Workman et
al. suggested that the concept of enzyme-directed bioreductive drug development can be
utilized in the structure-based design of improved bioreductive anticancer drugs.6,7
In structure-based design the information obtained from the interactions and
composite structure of the target protein-ligand is utilized to design improved ligands
with high binding affinity for target proteins implicated in diseases.2-4,8 A profound
understanding of ligand-protein interactions in the active site of the target greatly
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contributes to the corresponding structure-activity relationship (SAR) studies, which in
turn are the crucial components in the context of structure-based ligand design.9
Computer-aided docking techniques serve as time- and cost-efficient tools for structurebased design and decrease efforts of synthesis and biological testing of compounds.3,10
These techniques greatly contribute to this field since they facilitate extraction of
information on binding events and the molecular basis of ligand-protein interactions as
well as prediction of binding orientations and affinities of candidate compounds.2-4,11
This information then is utilized to design improvements to existing ligands.3 Another
major element in computer-aided structure-based design is the ability to quickly screen
designed ligands against a target protein via docking methods and accurately rank them
for the binding affinity.3 At the end of the process, a small group of the most promising
designed ligands is synthesized and considered for biological tests.3
Suleman et al. rationally designed a series of benzimidazolediones and performed
molecular modeling studies on the compounds with NQO1.8 Correlation of the modeling
data with the substrate specificity of the compounds for NQO1 determined the structural
features required for high affinity of the compounds for NQO1, the enzymatic
mechanism of NQO1 and the role of amino acid residues in the active site.8 They
performed docking studies via manual docking of each compound into the active site and
considered each NQO1-compound complex as a separate model to gain insight to binding
events of that specific compound.8 However, they did not develop a general model of the
NQO1 active site that could be used in an automatic docking process.8 They suggested
that the developed models will be used to develop novel NQO1-activated antitumor
agents and to predict the substrate specificity of the compounds.8
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This present study was conducted to design more optimal lavendamycin
substrates for NQO1 with increased selective cytotoxicity towards NQO1-rich cells using
our obtained SAR and docking data (See Chapters 2 and 3). Furthermore, the objective
was to determine whether our design criteria were fruitful and whether docking studies
performed using our recently developed in silico model of the NQO1 active site were
consistent with the biological results. We also sought to investigate the predictive power
of the model to correctly distinguish between good and poor NQO1 substrates. This is
the first study that attempts to perform structure-based lavendamycin design using SAR
and docking data and to relate the developed model and docking studies of lavendamycin
analogues with data from biological studies.

4.3

Materials and Methods

4.3.1 Chemistry. Designed N-acyllavendamycin esters and amides were
synthesized in Dr. Mohammad Behforouz’s laboratory at Ball State University.
4.3.2 In Silico Model of the NQO1 Active Site. The coordinates of the crystal
structure of human NQO1 complex with bound FAD and the indolequinone ARH019,
obtained from the Protein Data Bank (PDB ID code: 1H6912), were previously utilized as
a reference structure to develop the in silico model of the NQO1 active site (See Chapter
3).13 Briefly, the physiological dimer in the crystal unit was used for docking purposes.
In order to develop the model, we previously superposed the energy-minimized
compound MB-353 to the coordinates of the original reference ligand ARH019 such that
overlap was optimal. Ligand MB-353 was again energy minimized in the context of the
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active site and therefore the position of the ligand within the pocket was considered
optimized for the purpose of this study. The active site was then defined as all the amino
acid residues confined within 6.5 Å radius sphere centered on the superposed ligand MB353. The coordinates were locally minimized and subjected to energy minimization with
minimal iterations (100) by Powell minimization standard method using Minimize Subset
option within SYBYL. This option automatically selected 24 seed amino acid residues
surrounding the superposed ligand MB-353 to perform the local minimization. Default
parameters and values within the minimization dialog were used except where otherwise
mentioned. This procedure yielded a weighted root-mean-square distance of 0.26 Å
between the 24 corresponding non-minimized and minimized residues in the structures.
The file of the composite structure containing ligand MB-353 and FAD was saved. The
composite structure without MB-353 utilized as the in silico model of the NQO1 active
site for docking studies. Ligand MB-353 served as the reference ligand for the docking
studies. Docking calculations were performed using one of the two identical active sites.
4.3.3 Ligand Preparation. The structures of ligands were sketched and
prepared as MOL2 files employing the Sketch Molecule module of SYBYL 7.0 software
suite14 (Tripos, Inc.; St. Louis, MO). Initially sketched Ligands were subjected to energy
minimization (10,000 iterations) by Powell minimization standard method. Initial
Optimization and Termination parameters were set to None and Energy Change options,
respectively. Default parameters and values within the minimization dialog (Minimize
Details) were used except where otherwise noted. The final ligand conformational
coordinates were stored as MOL2 files within the database.
4.3.4 Docking. Flexible docking was performed using the FlexX module of
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SYBYL 7.0 software suite.14 FlexX is an automatic docking program for
conformationaly flexible ligands that employs the 3D structure of the target protein in
PDB format, and is capable of determining 30 possible conformations for each docked
ligand. The final rank order of the conformations is based on the free binding energy.
This program automatically selects the base fragment of a ligand (the ligand core). The
base fragment is then placed into the active site of the target protein using the algorithmic
approach called pose clustering that is based upon a pattern recognition paradigm.
Subsequent incremental reconstruction of the complete ligand molecule is then performed
by linking the remaining components.15,16 For the in silico model, the active site was
defined as all the amino acid residues confined within 6.5 Å radius sphere centered on the
superposed ligand MB-353. FAD was introduced to the active site as a heteroatom file in
MOL2 format.
4.3.5 Scoring Functions. The docked conformations of ligands were evaluated
and ranked using FlexX and four scoring functions implemented in the CSCORE module
in SYBYL. CSCORE is a consensus scoring program that integrates multiple wellknown scoring functions such as FlexX, ChemScore,17 D-Score,18 G-Score19 and PMFScore20 to evaluate docked conformations. Individual scoring functions are used to
predict the affinity of the ligand binding to a target protein. CSCORE creates columns in
a molecular spreadsheet that contain raw scores for each individual scoring function. The
consensus column contains integers that range from 0 to 5; where 5 is the best fit to the
model. Docked conformations whose scores exceed the threshold for a particular
function contribute one to the value of the consensus, whereas those with scores below
the threshold add a zero.
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4.3.6 Molecular Graphics System. The molecular graphics images and surface
representations were prepared with PyMOL molecular graphics system version
PyMOLX11Hybrid 0.9721 (Delano Scientific, San Carlos, CA, USA). The data of the
coordinates of the NQO1 complex with bound FAD and docked conformations of ligands
were prepared in PDB format as PyMOL input files. PyMOL session files of the NQO1
active site with docked conformations of ligands and the superimposition of clustered
conformations were created. The images were then stored as graphic files.
4.3.7 Cell Culture. BE human colon adenocarcinoma cells and stably NQO1transfected BE-NQ cells22 were a gift from Dr. David Ross (University of Colorado
Health Sciences Center, Denver, CO). Cells were grown in a minimum essential medium
(MEM) with Earle’s salts, non-essential amino acids, L-glutamine and
penicillin/streptomycin, and supplemented with 10% fetal bovine serum (FBS), sodium
bicarbonate and HEPES. Cell culture medium and supplements were obtained from
Gibco, Invitrogen Co., Grand Island, NY. The cells were incubated at 37°C under a
humidified atmosphere containing 5% CO2.
4.3.8 Cytochrome c Assay. Lavendamycin analogue reduction was monitored
using a spectrophotometric assay in which the rate of reduction of cytochrome c was
quantified at 550 nm. Briefly, the assay mixture contained cytochrome c (70 µM),
NADH (1 mM), human recombinant NQO1 (0.1-3 µg) (gift from Dr. David Ross,
University of Colorado Health Sciences Center, Denver, CO) and lavendamycins (25
µM) in a final volume of 1 mL Tris-HCl (25 mM, pH 7.4) containing 0.7 mg/mL BSA
and 0.1% Tween-20. Reactions were carried out at room temperature and started by the
addition of NADH. Rates of reduction were calculated from the initial linear part of the
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reaction curve (0-30 s), and results were expressed in terms of µmol of cytochrome c
reduced/min/mg of NQO1 using a molar extinction coefficient of 21.1 mM-1 cm-1 for
cytochrome c. All reactions were carried out at least in triplicate.
4.3.9 MTT Assay. Growth inhibition was determined using the MTT
colorimetric assay. Cells were plated in 96-well plates at a density of 10,000 cells/mL
and allowed to attach overnight (16 h). Lavendamycin analogue solutions were applied
in medium for 2 hours. Lavendamycin analogue solutions were removed and replaced
with fresh medium, and the plates were incubated at 37 °C under a humidified
atmosphere containing 5% CO2 for 4-5 days. MTT (50 µg) was added and the cells were
incubated for another 4 hours. Medium/MTT solutions were removed carefully by
aspiration, the MTT formazan crystals were dissolved in 100 µL DMSO, and absorbance
was determined on a plate reader at 560 nm. IC50 values (concentration at which cell
survival equals 50% of control) were determined from semi-log plots of percent of
control vs. concentration. Selectivity ratios were defined as the IC50 value for the BE cell
line divided by the IC50 value for the BE-NQ cell line.

4.4

Results and Discussion

4.4.1 Structure-based Design. Lavendamycin analogues MB-116, -137, -100
and -340 (Chart 4.1) were designed utilizing the criteria obtained from our SAR and
docking study (See Chapters 2 and 3),13 and other recent NQO1-related literature. The
structure-based design criteria for substituent features at key positions are detailed in the
following sections.
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Quinolinedione-7-position (R1) (Chart 4.1): (1) Small to medium size
substituents, preferably NH2 or NHCOCH3 group13 that do not produce steric interactions
with the key residues of the active site including the internal wall (Trp-105/Phe-106)
(applied to MB-116, -137 and -340).8,23,24 The substituents should also be capable of
hydrogen bond formation with the FAD cofactor and/or the key amino acid residues of
the active site including Tyr-126, -128 and His-161.13 Faig et al. determined that
positions of the aziridinylbenzoquinone RH1 that point to the inner part of the NQO1
active site could accommodate only small substituents.12 (2) Substituents that can
intercalate between and/or form van der Waals interactions with the Trp-105/Phe-106
mini-pocket (applied to MB-100).8,23 A previous study demonstrated that an aziridinyl
group at C5 position of EO9 can form favorable van der Waals interactions with Trp106.23 Another study determined that van der Waals interactions between the C5
aziridine ring of CB1954, 5-aziridinyl-2,4-dinitrobenzamide,25 and Trp-105 is an
important factor in the binding of this prodrug.25 Unsubstituted pyrrolo rings in
dipyrroloimidazobenzimidazole and dipyridoimidazobenzimidazole compounds can
sandwich between the Trp-105/Phe-106 residues and form van der Waals interactions to
increase NQO1 substrate specificity.8 (3) No large substituents are allowed due to
increased steric hindrance with the internal wall that can result in unfavorable positioning
of the quinoline-5,8-dione moiety of lavendamycin analogues for hydride ion reception
from FADH2 and quinone reduction (applied to MB-116, -137, -100 and -340).8,13 A
study by Suleman et al. demonstrated that dipyrroloimidazobenzimidazole compounds
with both pyrrolo rings bearing bulky substituents were excluded from the active site due
to steric interactions.8
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Chart 4.1. Chemical structures of the lavendamycin analogues MB-73, -100, -116, -137,
and -340 and with substituent positions indicated by R1, R2 and R3.
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CO2(CH2)2OH

Quinolinedione-6-position (R2) (Chart 4.1): Absence of substituents in this
position is highly preferred. Simultaneous placing of substituents at both R1 and R2
increases steric interactions of lavendamycin ligands with the internal wall of the active
site.13 It has been reported that 1,4-naphthoquinones with small substituents such as an
aziridine ring or CH3 at C2 and no substituents at C3 (C2 and C3 positions point to the
inside of the active side) are good substrates for NQO1.26 Increased bulkiness of
substituents at the C5 position of indolequinones dramatically reduced rates of reduction
by NQO1.12,23 Previous SAR studies have demonstrated that 7-aminoquinoline-5,8-dione
is an essential moiety in determining the cytotoxic and antitumor activity of
quinolinedione antibiotics.27,28 Therefore, substituent placement at the R1 position over
R2 is highly desirable (applied to MB-116, -137, -100 and -340).
Indolopyridine-2'-position (R3) (Chart 4.1): (1) Substituents that are capable of
hydrogen bond formation with the FAD cofactor and/or the key residues of the active site
including Gly-149 and Gly-150 (applied to MB-100 and -340).13 The 3-hydroxymethyl
group of ARH019 that points towards the outside of the active site forms a hydrogen
bond with the Tyr-128 OH.12 (2) Substituents (including aliphatic chains) that are
capable of formation of van der Waals interactions with the key residues of the NQO1
active site (applied to MB-116 and -137). Compound MB-83 (See Chapter 2),
demethyllavendamycin n-octyl ester,29 possesses a large n-octyl ester substituent at the R3
position and is a good NQO1 substrate with high selective toxicity towards NQO1-rich
cancer cells.13
Utilizing the design criteria we designed compounds MB-116, -137, -100 and 340 with small or medium size substituents at R1, no substituent at R2 and small to large
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substituents at R3. The substituents at R1 and R3 are expected to form hydrogen bond
and/or van der Waals interactions with FAD and/or the amino acid residues of the active
site such as Trp-105, Phe-106, Tyr-126, -128, -Gly-149, -150 and His-161. The docking
studies of the compounds using the in silico model were performed to predict the
substrate specificity of the compounds for NQO1, to examine the predictive power of the
model, to relate the model and docking studies with the metabolism and cytotoxicity
results, and to gain further insight into the binding events and the molecular basis of
lavendamycin agent-NQO1 interactions.
4.4.2 Docking Studies. Our laboratory recently developed a 1H69 crystal
structure-based in silico model of the NQO1 active site (See Chapter 3). In order to
further determine the predictive power of the model and correlation of the docking data
with biological results, we performed computational and comparative docking studies on
the structure-based designed lavendamycin analogues and the previously synthesized
compound MB-73. A practical model should be able to correctly predict the substrate
specificity of the docked compounds. The molecular modeling studies were performed
using SYBYL 7.0 software suite14 (Tripos, Inc.; St. Louis, MO). Flexible docking was
performed using the FlexX module of SYBYL that is capable of determining 30 possible
poses for each docked ligand.15,16 The docked conformations of ligands MB-116, -137, 73, -100 and -340 were evaluated and ranked using the CSCORE module in SYBYL,
from 0 to 5; where 5 was the best fit to the model. Table 4.1 displays the number of
conformations of the ligands in each score group of CSCORE function.
Ligands MB-116 and -340 possessed higher number of poses with optimal
CSCORE values compared to MB-73, -100 and -137 (Table 4.1). Visual screening of
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binding orientations of the poses and geometric post-docking analyses were performed.
The analyses included distance measurements and pose geometries that determined: (a)
hydrogen-bonding and van der Waals interactions of ligand poses with FAD and the key
residues of the NQO1 active site including Trp-105, Phe-106, Tyr-126, -128, -Gly-149, 150, His-161 and Phe-232 and (b) hydride ion transfer from the N5 of the FAD
isoalloxazine ring to the ligands at carbonyl oxygens (O5 or O8), ring carbon or
substituent atoms. Residue numbers in this report are those used in the Protein Data
Bank coordinates, PDB ID code: 1H69.12
The binding orientations of the ligands in the NQO1 active site were determined
by the positioning of quinone carbonyl oxygens towards the isoalloxazine ring atoms of
FAD and residues of the active site. Quinone substrates can bind to the NQO1 active site
in more than one orientation, and homologous compounds with different substituents may
bind to the NQO1 active site in different orientations.12,30 Only poses of the ligands with
CSCORE ≥ 4 were considered for further detailed post-docking analyses.
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Table 4.1. Number of poses of ligands MB-116, -137, -73, -100 and -340 in each score
group of CSCORE function.

MB

116

137

CSCORE

73

100

340

Number of Poses

0

7

6

5

9

5

1

4

9

10

9

3

2

5

1

6

7

2

3

5

11

4

3

5

4

4

3

5

1

10

5

5

0

0

1

5
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Ligands MB-116 and -137 were designed to possess highly similar chemical
structures with only a minor difference in the substituents at R3 (R3 substituents of MB116 and -137 are structural isomers). The purpose was to examine the role that R3
substituents play to impact the affinity of lavendamycin substrates for NQO1. Nine poses
of ligand MB-116 possessed CSCORE ≥ 4 compared to three poses of MB-137 (Table
4.1). None of the poses of MB-137 had a CSCORE = 5 (Table 4.1). Poses 1, 2, 4, 5 and
6 (CSCORE = 5) of MB-116 fell into one cluster in which the root mean square deviation
(RMSD) of the poses equaled zero for the quinolinedione and indolopyridine moieties
atoms, and the difference was in the binding orientation of the CONH(CH2)3CH3 group in
the NQO1 active site (Figure 4.1a). All of the poses of MB-116 entered the active site by
the 5,8-dione moiety where the carbonyl oxygen O8 compared to O5 was positioned
closer to Tyr-126, -128 and FAD similar to the binding orientation of indolequinone EO9
(Figure 4.1a and Table 4.2).12,23 The binding orientations of the MB-116 poses in the
cluster are considered as preferred binding orientations of MB-116 since these are the
binding orientations of the poses with high CSCORE of 5 (Figure 4.1a).
One crucial determining factor of NQO1 substrate binding strength in the NQO1
active site is the capability to form hydrogen-bonding and/or van der Waals interactions
with FAD and/or residues of the active site.8,12,25,30 Good substrates for NQO1 such as
RH1, EO9 and CB1954 are capable of hydrogen-bonding interactions with the key
residues of the NQO1 active site.12,25 Duroquinone, a tetramethyl analogue of
benzoquinone, binds to the NQO1 active site through interactions with FAD and several
hydrophilic and hydrophobic residues.31
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Figure 4.1. Molecular models of the poses of ligand MB-116 docked into the NQO1
active site.

a)

b)
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Figure 4.1. Molecular models of the poses of ligand MB-116 docked into the NQO1
active site. a) View of the superposition of the docked poses 1, 2, 4, 5 and 6 of MB-116
(magenta, cyan, yellow, salmon and blue) (CSCORE = 5) in the NQO1 active site. b)
Molecular model of the pose 1 of MB-116 (magenta) (CSCORE = 5) docked into the
NQO1 active site. In (b) the Tyr-128 OH formed hydrogen bonds with the carbonyl
oxygen O8, the NH of the indole ring of the indolopyridine moiety and the carbonyl
oxygen of the quinolinedione-7-position substituent. The carbonyl oxygen O5 formed a
hydrogen bond with the NH of His 161. The NH of the quinolinedione-7-position
substituent also formed hydrogen bonds with the N1, N5 and N10 of FAD. The
CONH(CH2)3CH3 group of the indolopyridine moiety further stabilized the binding by
forming van der Waals interactions with Phe-232. In (a) and (b) residues of the active
site (green), FAD (blue), and MB-116 are represented as stick models. In (b) the rest of
the structure is represented as a secondary structure cartoon. The atoms are colored: red,
oxygen atoms; blue, nitrogen atoms; orange, phosphorus atoms and white, hydrogen
atoms. Hydrogen bonds are represented as black dashed lines.
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Table 4.2. Geometric post-docking analysis and measurements of five poses (CSCORE
= 5) and four poses (CSCORE = 4) of ligand MB-116 in the NQO1 active site.

Pa

Cb

O5

O5

O8

O8

N5

N5

N5

N5

-

-

-

-

-

-

-

-

Tyr126

Tyr128

Tyr126

Tyr128

O5

O8

C6

C7

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

1

5

9.174

6.143

4.862

2.077

7.786

5.006

5.515

4.622

2

5

9.174

6.143

4.862

2.077

7.786

5.006

5.515

4.622

4

5

9.174

6.143

4.862

2.077

7.786

5.006

5.515

4.622

5

5

9.174

6.143

4.862

2.077

7.786

5.006

5.515

4.622

6

5

9.174

6.143

4.862

2.077

7.786

5.006

5.515

4.622

3

4

9.417

6.196

4.804

1.802

7.953

5.281

5.714

4.863

7

4

9.260

6.085

4.774

1.899

7.772

5.187

5.532

4.697

14

4

9.180

6.242

4.878

2.123

7.618

4.960

5.375

4.515

25

4

9.167

6.198

4.882

2.081

7.692

5.016

5.427

4.560

a

P = Pose

b

C = CSCORE
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Among the poses of ligand MB-116, poses 1, 2, 4, 5 and 6 formed the highest
number of hydrogen bonds and van der Waals interactions in the active site of the
enzyme. For pose 1 of MB-116, the Tyr-128 OH formed hydrogen bonds with the
carbonyl oxygen O8, the NH of the indole ring of the indolopyridine moiety and the
carbonyl oxygen of the quinolinedione-7-position substituent (Figure 4.1b). The
carbonyl oxygen O5 formed a hydrogen bond with the NH of His 161 (Figure 4.1b). The
NH of the quinolinedione-7-position substituent also formed hydrogen bonds with the
N1, N5 and N10 of FAD (Figure 4.1b). The CONH(CH2)3CH3 group of the
indolopyridine moiety further stabilized the binding by forming van der Waals
interactions with Phe-232 (Figure 4.1b). Poses 2, 4, 5 and 6 displayed the same
interactions as pose 1 (Table 4.2). The model determined high number of poses of MB116 with optimum CSCORE (≥ 4) that are capable of hydrogen bond and van der Waals
formation in the NQO1 active site suggesting that this compound is a good substrate for
NQO1.
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However, of thirty poses of MB-137 only poses 1, 2 and 4 merited further
considerations (CSCORE = 4) and the rest possessed CSCORE ≤ 3. None of the poses of
MB-137 had a CSCORE = 5 (Table 4.1). Poses 1, 2 and 4 of MB-137 entered the active
site by the 5,8-dione moiety similar to the poses of MB-116 (Figure 4.2a and Table 4.3).
Although these poses formed hydrogen bonds with FAD and the residues of the NQO1
active site, the number of total hydrogen bonds was lower than that for the poses of MB116 (hydrogen bonds not shown). Furthermore, none of poses 1, 2 and 4 of MB-137
formed van der Waals interactions with Phe-232 compared to the poses of MB-116
suggesting lower binding affinity of MB-137 compared to MB-116 in the NQO1 active
site (Figures 4.2a and 4.2b). These docking studies performed using the in silico model
ranked MB-137 as a poor substrate for NQO1.
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Figure 4.2. Molecular models of the poses of ligand MB-137 docked into the NQO1
active site.

a)

b)
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Figure 4.2. Molecular models of the poses of ligand MB-137 docked into the NQO1
active site. a) View of the superposition of the docked poses 1, 2 and 4 of MB-137
(magenta, yellow and salmon) (CSCORE = 4) in the NQO1 active site. b) Molecular
model of the pose 1 of MB-137 (magenta) (CSCORE = 4) docked into the NQO1 active
site. In (a) and (b) residues of the active site (green), FAD (blue), and MB-137 are
represented as stick models. In (b) the rest of the structure is represented as a secondary
structure cartoon. The atoms are colored: red, oxygen atoms; blue, nitrogen atoms;
orange, phosphorus atoms and white, hydrogen atoms.
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Table 4.3. Geometric post-docking analysis and measurements of three poses of ligand
MB-137 (CSCORE = 4) in the NQO1 active site.

Pa Cb

O5

O5

O8

O8

N5

N5

N5

N5

-

-

-

-

-

-

-

-

Tyr126

Tyr128

Tyr126

Tyr128

O5

O8

C6

C7

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

1

4

9.402

6.193

4.802

1.828

7.933

5.246

5.689

4.831

2

4

9.402

6.193

4.802

1.828

7.933

5.246

5.689

4.831

4

4

9.268

6.084

4.692

1.770

7.739

5.240

5.504

4.691

a

P = Pose

b

C = CSCORE
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The important role that residue Phe-232 plays in contributing to the binding
affinity of NQO1 substrates has been further emphasized in recent studies.32,33 One study
indicated that the distance between Tyr-128 and Phe-232 residues in the NQO1 active
site increases dramatically from 4 Å in apo human NQO1 (PDB ID code: 1D4A31) and
NQO1-duroquinone complex (PDB ID code: 1DXO31) crystal structures to 12 Å in the
NQO1 complex with dicoumarol (NQO1 inhibitor) crystal structure.32 Another study
also determined that upon binding of the NQO1 inhibitor ES936, 5- methoxy-1,2dimethyl-3-(4-nitrophenoxymethyl)indole-4,7- dione,33 to the NQO1 active site, Tyr-128
and Phe-232 exhibit the largest displacement.33 These studies suggest that proper
positioning of phe-232 could contribute to binding affinity of NQO1 substrates which is
disturbed upon binding of inhibitors. Overall, a higher number of poses of ligand MB116 compared to MB-137 possessed optimum CSCORE, formed hydrogen bonding
interactions (van der Waals interactions only in poses of MB-116) and had favorable
binding orientation for hydride ion reception and quinone reduction (Tables 4.1, 4.2 and
4.3). The in silico model distinguished the two highly similar analogues MB-116 and
MB-137 as the good and poor substrates, respectively.
Compound MB-100 was designed to investigate whether an aromatic amide group
at R1 is capable of intercalating between Trp-105 and Phe-106 residues and forming van
der Waals interactions to increase NQO1 substrate specificity. Docking studies of MB100 were performed to observe how the model would rank this compound as an NQO1
substrate. Only two poses 7 and 30 of ligand MB-100 possessed CSCORE ≥ 4 (Table
4.1). These poses entered the active site by the 5,8-dione moiety similar to the poses of
MB-116 and MB-137 (Figure 4.3a and Table 4.4).
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Figure 4.3. Molecular models of the poses of ligand MB-100 docked into the NQO1
active site.

a)

b)
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Figure 4.3. Molecular models of the poses of ligand MB-100 docked into the NQO1
active site. a) View of the superposition of the docked poses 7 and 30 of MB-100
(orange and magenta) (CSCORE = 5 and 4) in the NQO1 active site. b) Molecular model
of the pose 2 of MB-100 (yellow) (CSCORE = 3) docked into the NQO1 active site. In
(a) and (b) residues of the active site (green), FAD (blue), and MB-100 are represented as
stick models and the rest of the structure is represented as a secondary structure cartoon.
The atoms are colored: red, oxygen atoms; blue, nitrogen atoms; orange, phosphorus
atoms and white, hydrogen atoms.
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Table 4.4. Geometric post-docking analysis and measurements of two poses of ligand
MB-100 (CSCORE = 4 and 5) in the NQO1 active site.

Pa

Cb

O5

O5

O8

O8

N5

N5

N5

N5

-

-

-

-

-

-

-

-

Tyr126

Tyr128

Tyr126

Tyr128

O5

O8

C6

C7

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

7

5

9.585

6.455

4.785

1.780

7.759

5.236

5.664

4.873

30

4

9.454

6.273

4.610

1.639

7.669

5.247

5.562

4.793

a

P = Pose

b

C = CSCORE
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The two poses of MB-100 (7 and 30) formed few hydrogen bonds with FAD and
the residues of the NQO1 active site (hydrogen bonds not shown). The other twentyeight poses with CSCORE ≤ 3 were excluded from the NQO1 active site including pose 2
(CSCORE = 3) (Figure 4.3b). The NHCO-2-furyl group of poses 7 and 30 did not
intercalate between the Trp-105 and Phe-106 residues, suggesting the lack of Van der
Waals interactions with the Trp-105/Phe-106 mini-pocket and presence of possible steric
interactions with the residues Trp-105 and Phe-106 (Figure 4.3a). Previous studies have
indicated that the Trp-105/Phe-106 mini-pocket can play a crucial role in impacting the
substrate specificity of NQO1 ligands.8,23,34 If the corresponding substituent is able to
intercalate between Trp-105 and Phe-106 and form van der Waals interactions with these
residues, the binding affinity of the quinone substrate in the NQO1 active site will
increase.8,23 Our model ranked ligand MB-100 as a poor substrate for NQO1.
Compound MB-340 was designed after MB-353, a good NQO1 lavendamycin
substrate, to create another good substrate. Fifteen poses of ligand MB-340 possessed
CSCORE ≥ 4 (Table 4.1). Poses 1, 2, 4 and 7 (CSCORE = 5) of MB-340 entered the
active site by the 5,8-dione moiety where the carbonyl oxygen O8 compared to O5 was
positioned closer to Tyr-126, -128 and FAD (Figure 4.4a and Table 4.5). Among five
poses of MB-340 with CSCORE = 5, pose 8 entered the active site in a different
orientation compared to poses 1, 2, 4 and 7 where carbonyl oxygen O5 compared to O8
was positioned closer to Tyr-126, -128 and FAD (Figure 4.4b and Table 4.5). Different
binding orientations of quinone substrates that can facilitate hydride ion reception from
the FAD N5 to the substrates can be tolerated in the active site.12,30
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Figure 4.4. Molecular models of the poses of ligand MB-340 docked into the NQO1
active site.
a)

b)

c)
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Figure 4.4. Molecular models of the poses of ligand MB-340 docked into the NQO1
active site. a) View of the superposition of the docked poses 1, 2, 4 and 7 of MB-340
(cyan, magenta, yellow and salmon) (CSCORE = 5) in the NQO1 active site. b)
Molecular model of the pose 8 of MB-340 (orange) (CSCORE = 5) docked into the
NQO1 active site. c) Molecular model of the pose 4 of MB-340 (yellow) (CSCORE = 5)
docked into the NQO1 active site. In (c) the Tyr-128 OH formed hydrogen bonds with
the carbonyl oxygen O8 and the N1 of the quinoline ring of the pose 4 of MB-340. One
hydrogen atom of the NH2 substituent also formed hydrogen bonds with the N3 and O4
of FAD. The carbonyl oxygen O5 formed a hydrogen bond with the NH of His 161. The
OH of CO2(CH2)2OH at R3 further stabilized the binding by making a hydrogen bond to
one oxygen atom of the adenine phosphate of FAD. In (a), (b) and (c) residues of the
active site (green), FAD (blue), and MB-340 are represented as stick models. In (b) and
(c) the rest of the structure is represented as a secondary structure cartoon. The atoms are
colored: red, oxygen atoms; blue, nitrogen atoms; orange, phosphorus atoms and white,
hydrogen atoms. Hydrogen bonds are represented as black dashed lines.
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Table 4.5. Geometric post-docking analysis and measurements of five poses of ligand
MB-340 (CSCORE = 5) in the NQO1 active site.

Pa

Cb

O5

O5

O8

O8

N5

N5

N5

N5

-

-

-

-

-

-

-

-

Tyr126

Tyr128

Tyr126

Tyr128

O5

O8

C6

C7

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

(Å)

1

5

9.662

6.593

4.421

2.243

7.925

4.627

5.978

5.027

2

5

9.519

6.480

4.375

1.917

7.800

4.829

5.854

4.977

4

5

9.631

6.564

4.374

2.281

7.774

4.533

5.705

4.738

7

5

9.597

6.568

4.597

2.177

7.787

4.692

5.816

4.904

8

5

3.767

1.862

8.938

5.903

4.596

7.253

4.557

5.355

a

P = Pose

b

C = CSCORE
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Among the poses of ligand MB-340, poses 1, 2, 4 and 7 formed the highest
number of hydrogen bonds in the active site of the enzyme. The Tyr-128 OH formed
hydrogen bonds with the carbonyl oxygen O8 and the N1 of the quinoline ring of pose 4
of MB-340 (Figure 4.4c). One hydrogen atom of the R1 NH2 substituent also formed
hydrogen bonds with the N3 and O4 of FAD. The carbonyl oxygen O5 formed a
hydrogen bond with the NH of His 161 (Figure 4.4c). The OH of CO2(CH2)2OH at R3
further stabilized the binding by making a hydrogen bond to one oxygen atom of the
adenine phosphate of FAD (Figure 4.4c). However, pose 8 among poses of MB-340 with
CSCORE = 5, formed the lowest number of hydrogen bonds. This suggests that the
binding orientations of poses 1, 2, 4 and 7 are the preferred binding orientations for
ligand MB-340 over that for pose 8 (Figures 4.4a and 4.4b). The in silico model
recognized MB-340 as a good substrate for NQO1.
Compound MB-73 was selected from previously synthesized lavendamycin
analogues. According to our SAR studies this compound should be a poor substrate for
NQO1 due to the presence of the large NHCOC3H7-n group at the R1 position that could
create steric interactions inside the NQO1 active site. Therefore, this compound was
selected for docking studies to observe how the model would rank it as an NQO1
substrate. None of the MB-73 conformations had a CSCORE = 5 (Table 4.1). All of the
poses of MB-73 including poses 2, 5, 6, 21 and 25 (CSCORE = 4) fell into one cluster
that yielded an RMSD equal to 0 Å for the quinolinedione and indolopyridine moieties
atoms (Figure 4.5a). The difference was in the binding orientations of the NHCOC3H7-n
and CO2C2H4CH(CH3)2 groups (Figure 4.5a). All thirty poses of MB-73 including 2
were excluded from the NQO1 active site (Only pose 2 is shown) (Figure 4.5b). This
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exclusion could be related to the steric hindrance produced by the large NHCOC3H7-n
substituent against the Trp-105/Phe-106 wall that could be further enhanced by the
contributing steric effect produced by the large CO2C2H4CH(CH3)2 group. Ligand MB73 was ranked as a poor substrate for NQO1.
The molecular docking studies demonstrated that Ligands MB-116 and MB-340
possessed an increased number of possible poses with optimum CSCORE and favorable
binding orientations to promote hydrogen bonding and van der Waals interactions,
hydride ion reception and quinone reduction compared to ligands MB-137, -100 and -73.
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Figure 4.5. Molecular models of the poses of ligand MB-73 docked into the NQO1
active site.

a)

b)
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Figure 4.5. Molecular models of the poses of ligand MB-73 docked into the NQO1
active site. a) View of the superposition of the docked poses 2, 5, 6, 21 and 25 of MB-73
(magenta, cyan, blue, salmon and yellow) (CSCORE = 4) in the NQO1 active site. b)
Molecular model of the pose 2 of MB-73 (magenta) (CSCORE = 4) docked into the
NQO1 active site. In (a) and (b) residues of the active site (green), FAD (blue) and MB73 are represented as stick models. In (b) the rest of the structure is represented as a
secondary structure cartoon. The atoms are colored: red, oxygen atoms; blue, nitrogen
atoms; orange, phosphorus atoms and white, hydrogen atoms.
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4.4.3 Metabolism Studies. Metabolism of the lavendamycin analogues by
recombinant human NQO1 was examined. Reduction rates by NQO1 were measured
using a spectrophotometic assay that employs cytochrome c as the terminal electron
acceptor23 and gives initial rates of lavendamycin analogue reduction (Table 4.6). The
initial reduction rates (µmol cytochrome c reduced/min/mg NQO1) were calculated from
the linear portion (0-30 s) of the reaction graphs.
Compound MB-116 with the NHCOCH3 and CONH(CH2)3CH3 groups at R1 and
R3 positions, respectively, displayed the highest metabolism rate by NQO1 among the
compounds (Table 4.6). The NHCOCH3 group, a medium size substituent, did not
produce steric hindrance with the internal wall of the NQO1 active site resulting in
favorable positioning of MB-116 for hydride ion reception from FADH2 and quinone
reduction. Our docking studies determined that this group was also capable of hydrogen
bonding with FAD and the key residues of the active site. These studies also
demonstrated that the CONH(CH2)3CH3 group at the R3 position (pointing towards the
outside of the active site) was capable of forming van der Waals interactions with Phe232 residue of the NQO1 active site. This could be a contributing factor to the substrate
specificity of this compound. Compound MB-83 (See Chapter 2), a studied
lavendamycin analogue, with the straight chain n-octyl ester substituent at the R3 position
(CO2C8H17-n) was determined to be a good substrate for the enzyme similar to MB-116.13
The docking studies also indicated ligand MB-116 as a good substrate for NQO1.
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Table 4.6. Metabolism of lavendamycin analogues by recombinant human NQO1
monitored by spectrophotometric cytochrome c assay.
O
R2
R1

N

N

R3

O
HN

MB

R1

R2

R3

Metabolism by NQO1
(µmol/min/mg)
(Cytochrome c
Reduction)

116

CH3CONH

H

CONH(CH2)3CH3

143 ± 11

137

CH3CONH

H

CONHCH(CH3)C2H5

4.9 ± 2.9

73

n-C3H7CONH

H

CO2C2H4CH(CH3)2

3.4 ± 1.7

100

2-Furyl-CONH

H

CO2CH3

7.0 ± 1.5

340

NH2

H

CO2(CH2)2OH

60 ± 8
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Although MB-137 possessed a similar chemical structure to MB-116 (the best
substrate), it was a poor substrate for NQO1 (Table 4.6) that was in accordance with the
docking data. Compounds MB-116 and -137 are structural isomers. The
CONH(CH2)3CH3 group at the R3 position of MB-116 is a large, non-bulky and straight
chain aliphatic group, whereas CONHCH(CH3)C2H5 at the R3 position of MB-137 is a
large, bulky and branched structural isomer of the former. According to our docking
studies, the branched configuration at R3 of MB-137 was not capable of forming van der
Waals interactions with the Phe-232 residue of the NQO1 active site due to active site
constraints and steric effects.
Compound MB-100 exhibited a low metabolism rate by NQO1 (Table 4.6) due to
the possible failure of the NHCO-2-furyl group at the R1 position to intercalate between
and form van der Waals interactions with the internal wall residues. Docking studies
demonstrated that the lack of R1-substituent intercalation capability led to the unfavorable
positioning of MB-100 and loss of required hydrogen bonding and/or van der Waals
interactions with the active site residues. This compound was also ranked as a poor
substrate for NQO1 by the docking studies.
Compound MB-340 with a small NH2 group at R1 and CO2(CH2)2OH at R3
displayed a good reduction rate by the enzyme (Table 4.6). According to the docking
studies, favorable positioning of MB-340 in the active site was facilitated by lack of
steric interactions of the substituents with the residues of the active site and by hydrogen
bond formation with FAD and the residues of the NQO1 active site. Our docking studies
also indicated high binding affinities for MB-340. A previous study determined that
good indolequinone substrates for NQO1 including EO9 possessed a hydroxymethyl

152

group at the analogous C3 position.23 Furthermore, RH1, which is a good substrate for
NQO1, possesses a CH2OH group at C3 position.35,36 We also determined that
compound MB-353 (See Chapter 2), decarboxy-2'-(hydroxymethyl)demethyllavendamycin,13 that possessed an NH2 group at R1 and CH2OH at R3 was a
good substrate for NQO1.13
Compound MB-73 with NHCOC3H7-n and isoamyl ester groups at the R1 and R3
positions, respectively, exhibited the lowest metabolism rate by NQO1 and ranked as the
poorest substrate (Table 4.6). The recently studied lavendamycin analogue MB-50, 7-Nacetyldemethyllavendamycin isoamyl ester,13 with an acetamide group at R1 position and
isoamyl ester group at the R3 position displayed a reduction rate 12-fold higher than MB73 (See Chapter 2). The decreased reduction rate of MB-73 compared to MB-50 can be
explained by apparent steric hindrance between the quinolinedione moiety of MB-73 and
the NQO1 active site caused by the large NHCOC3H7-n group at R1 compared to
NHCOCH3 in MB-50. This steric interaction could result in exclusion of MB-73 from
the active site with subsequent poor hydride ion reception and quinone reduction
capability. MB-73 was also ranked as a poor substrate by our docking studies.
Addition of NH2 or NHCOCH3 groups at R1 and CO2(CH2)2OH or
CONH(CH2)3CH3 at R3 had the greatest positive impact on substrate specificity
compared to other substituents at these positions. The best substrates were the 2'CONH(CH2)3CH3-7-NHCOCH3 (MB-116) and 2'-CO2(CH2)2OH-7-NH2 (MB-340)
derivatives with reduction rates of 143 ± 11 and 60 ± 8 µmol/min/mg NQO1, respectively
(Table 4.6).
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4.4.4 In Vitro Cytotoxicity. Cytotoxicity studies were also performed on the
lavendamycin analogues with cell survival being determined by the colorimetric MTT
assay. We previously demonstrated an excellent positive linear correlation between the
IC50 values (the chemosensitivity results) of the clonogenic and MTT assays for
lavendamycin analogues (See Chapter 2).13 We utilized the BE human colon
adenocarcinoma cells stably transfected with human NQO1 cDNA.36 The BE cells had
no measurable NQO1 activity whereas activity in the transfected cells (BE-NQ) was 664
nmol/min/mg total cell protein using dichlorophenolindophenol (DCPIP) as the standard
electron acceptor. In this study the cytotoxicity of the lavendamycin analogues (Table
4.7) has been compared in these cell lines.
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Table 4.7. Cytotoxicity of lavendamycin analogues towards BE (NQO1-deficient) and
BE-NQ (NQO1-rich) human colon adenocarcinoma cell lines.
O
R2
R1

N

N

R3

O
HN

MB

R1

R2

R3

Cytotoxicity IC50 (µM)

Selectivity
Ratio
[IC50 (BE) /

BE-NQ

BE

IC50 (BENQ)]

116

CH3CONH

H

CONH(CH2)3CH3

1.7 ± 0.1

50.3 ± 1.5

30

137

CH3CONH

H

CONHCH(CH3)C2H5

>50

>50

-

73

n-C3H7CONH

H

CO2C2H4CH(CH3)2

>50

>50

-

100

2-Furyl-CONH

H

CO2CH3

47 ± 3

49.0 ± 6.5

1

340

NH2

H

CO2(CH2)2OH

0.5 ± 0.0

3.3 ± 0.2

7
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Designed analogues such as MB-116 and MB-340 that were good substrates for
NQO1 (Table 4.6) were also more toxic to the NQO1-rich BE-NQ cell line than the
NQO1-deficient BE cell line (Table 4.7). Compounds MB-116 and MB-340, the best
substrates for NQO1 (Table 4.6), had the greatest differential toxicity with a selectivity
ratio [IC50 (BE) / IC50 (BE-NQ)] of 30 and 7, respectively (Table 4.7). Our previous
study also determined that good lavendamycin substrates for NQO1 were selectively
toxic towards BE-NQ versus BE cells (See Chapter 2).13 Compounds MB-83, -353, -97,
demethyllavendamycin amide,29 and -22, lavendamycin methyl ester,37 exhibited high
selective toxicity toward BE-NQ cells (selectivity ratios = 10, 11, 9 and 9, respectively)
(See Chapter 2).13 Compound MB-97 was also reported to highly reduce the colony
outgrowth of A549 human lung carcinoma cells,38 and it displayed promising cytotoxic
and antitumor activities in the National Cancer Institute’s (NCI) 60-cell line panel and in
vivo hollow fiber tumorigenesis assay.38
Lavendamycin analogues, MB-137, -73 and -100 that were poor substrates for
NQO1 (Table 4.6) demonstrated no selective toxicity toward BE-NQ cells or had no
measurable cytotoxicity (IC50 > 50 µM) (Table 4.7). Overall, our results suggested that
the best lavendamycin substrates for NQO1 were also the most selectively toxic to the
high-NQO1 BE-NQ cell line compared to NQO1-deficient BE cells, consistent with our
previous study (See Chapter 2).13
It has been reported that lavendamycin analogues possess low animal toxicity
especially compared to streptonigrin (SN), a good substrate for NQO1 with high toxicity,
and the parent lavendamycin compound.29,39 The NCI in vivo studies have reported that
the maximum tolerated dose of three lavendamycin analogues MB-22, -76 and -97 in
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mice is 400 mg/kg which is 31 and 1000 times higher than that for lavendamycin and SN,
respectively.29,39 To obtain a preliminary assessment of the safety of lavendamycin
analogues, the lavendamycin analogue MB-116 was studied along with SN for toxicity to
normal cells using MMT assay. Human aortic endothelial cells (HAEC) that were treated
for 2 hours with either SN or MB-116 were used. SN (IC50 = 0.47 µM) was 25 times
more toxic to the endothelial cells than MB-116 (IC50 = 11.8 µM), suggesting that
lavendamycins may have a greater safety margin than SN. Further studies in future will
be required to obtain a broad range of safety assessment data on lavendamycin analogues
to consider these agents as promising chemotherapeutic candidates.

4.5

Conclusions

A number of novel lavendamycin anologues were designed and synthesized.
Addition of NH2 or NHCOCH3 groups at R1 and CO2(CH2)2OH or CONH(CH2)3CH3 at
R3 had the greatest positive impact on substrate specificity compared to other substituents
at these positions. The best substrates were the 2'-CONH(CH2)3CH3-7-NHCOCH3 (MB116) and 2'-CO2(CH2)2OH-7-NH2 (MB-340) derivatives and were also the most
selectively toxic to the NQO1-rich BE-NQ cell line compared to the NQO1-deficient BE
cell line. This study determined that the structure-based design criteria were productive,
resulting in the design of two analogues with high substrate specificity and selective
toxicity toward the NQO1-rich cells. It also indicated that the in silico model of the
NQO1 active site correctly distinguished good and poor NQO1 substrates suggesting the
model possessed practical predictive power. The docking data were in agreement with
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the biological results. Therefore, the in silico model of the NQO1 active site could be
utilized as a predictive, time- and cost-efficient tool in NQO1-directed lavendamycin
antitumor agent development.
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Chapter 5
Mechanisms of Lavendamycin Antitumor Agent Toxicity: NAD(P)H:Quinone
Oxidoreductase 1 (NQO1)-mediated Induction of Oxidative Stress and Apoptosis

5.1

Abstract

Lavendamycin antitumor agents that are good substrates for NQO1 are selectively
toxic to tumor cells with elevated NQO1 activity (See Chapter 2). The purpose of this
study was to investigate the mechanisms of NQO1-mediated selective cytotoxicity of
good lavendamycin substrates towards human colon adenocarcinoma NQO1-rich BE-NQ
cells compared to NQO1-deficient BE cells. Lavendamycin analogues possess structural
similarity to streptonigrin (SN), a good redox-cycling substrate for NQO1 that produces
large quantities of reactive oxygen species (ROS) after reduction by NQO1. Therefore,
we examined whether good lavendamycin substrates for NQO1 could induce NQO1mediated oxidative stress and subsequent apoptosis in BE-NQ cells. Biomarkers of
oxidative stress including formation of 8-hydroxy-2'-deoxyguanosine (8-oxo-2dG), an
indicator of oxidative DNA damage, and depletion of the reduced form of glutathione
(GSH) in the cells were investigated. BE and BE-NQ cells were treated with MB-353
(NQO1 good substrate, reduction rate = 263 ± 30 µmol/min/mg NQO1) and MB-323
(NQO1 poor substrate, reduction rate = 0.1 ± 0.1 µmol/min/mg NQO1). An HPLC-based
analysis was utilized to determine levels of 8-oxo-2dG and 2′-deoxyguanosine (2-dG) in
the cells, and the molar ratio, 8-oxo-2dG (fmol)/2-dG (nmol). Among MB-353 treated
cells, a significant increase in the molar ratio of 8-oxo-2dG to 2-dG was observed only in
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BE-NQ cells demonstrating the importance of NQO1 in selective induction of oxidative
DNA damage in BE-NQ cells by MB-353. No significant increase in the corresponding
molar ratio was observed in either cell line treated with MB-323 implying that NQO1mediated induction of oxidative DNA damage in BE-NQ cells was specific to MB-353.
Since we observed the production of oxidative DNA damage in BE-NQ cells by MB-353,
depletion of GSH as a biomarker of oxidative stress was also examined using a
colorimetric assay. MB-353 significantly decreased the levels of GSH in BE-NQ cells,
whereas no reduction in GSH levels was observed in BE cells suggesting an NQO1mediated selective depletion of GSH in BE-NQ cells by MB-353. No difference was
observed in the GSH levels in either cell line treated with MB-323 indicating that GSH
depletion in BE-NQ cells was specific to the good lavendamycin substrate, MB-353. In
addition, we hypothesized that the observed MB-353-induced oxidative stress in BE-NQ
cells could result in induction of apoptosis in these cells. Therefore, the role of NQO1 in
lavendamycin-induced apoptosis was examined using a colorimetric assay. MB-353
selectively induced apoptosis only in the BE-NQ cell line, while apoptosis induction was
not observed in either cell line treated with MB-323. Overall, our results demonstrated
that only the good lavendamycin substrate, MB-353, caused oxidative stress leading to
oxidative DNA damage and apoptosis in NQO1-rich BE-NQ cells at nM concentrations
via NQO1-mediated activation.

5.2

Introduction
Oxidative stress is defined as a condition in which overwhelming production of

reactive oxygen species (ROS) imposes an imbalance between ROS and antioxidant
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levels in excess of the former.1,2 Upon this challenge, inadequate levels of antioxidant
defense elements cannot efficiently neutralize ROS resulting in persistence of oxidative
stress and subsequent damage to cellular macromolecules.1,2 One crucial mechanism of
action for many anticancer agents is the production of ROS.3
Redox-cycling quinones undergo enzymatic reduction and autoxidation, and
subsequently generate ROS.4 Metabolism of redox-cycling quinones alters the
intracellular oxidant-antioxidant balance.4 Watanabe et al. have demonstrated that
NQO1-mediated autoxidation of the hydroquinone forms of menadione and 2,3dimethoxy-1,4-naphthoquinone (DMNQ) results in the generation of hydrogen peroxide
(H2O2) in lung epithelial A549-S cells treated with these agents.5 The menadione- and
DMNQ-induced production of H2O2 can be inhibited up to 90% and 100%, respectively,
by the NQO1 inhibitor, dicoumarol.5 In this study catalase prevented H2O2 accumulation
and protected A549-S cells from menadione- and DMNQ-induced cell death.5 Their
findings suggest that the observed H2O2 generation and cytotoxicity in menadione- and
DMNQ-treated A549-S cells were mainly due to NQO1-mediated autoxidation of the
corresponding hydroquinones.5 ROS-mediated cytotoxicity of phenanthrenequinone, 2amino-1,4-naphthoquinone and naphthazarin towards NQO1-enriched L5178Y/HBM10
lymphoblasts versus parental L5178Y cells has also been reported.6 Cytotoxic effects of
these compounds toward L5178Y/HBM10 mouse lymphoma cells were reduced when
treated by dicoumarol and catalase indicating NQO1-mediated redox cycling-related
cytotoxicity of these compounds.6 Another group determined NQO1-mediated,
autoxidation of variously substituted naphthoquinones in cell-free assays.7 In addition,
Beall et al. demonstrated NQO1-mediated redox cycling, selective cytotoxicity and
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induction of DNA strand breaks in NQO1-rich human colon carcinoma HT-29 cells
versus NQO1-deficient BE cells by streptonigrin (SN).8
Direct assessment of the levels of ROS to detect the presence of oxidative stress is
an impractical and unreliable approach due to the fact that ROS are short-lived and highly
reactive species.1,2 One alternative approach frequently used in some laboratories to
determine the presence of oxidative stress is to take advantage of its biological markers.1,2
Measurement of biological markers of oxidative DNA damage such as 8-hydroxy-2'deoxyguanosine (8-oxo-2dG) and the cellular glutathione (GSH) levels have been
routinely used as indices of oxidative stress induction.1,2
One method that can be utilized as an index of oxidative stress is the measurement
of 8-oxo-2dG, a product of oxidative DNA damage.1 8-Oxo-2dG is the most frequently
detected and studied oxidative DNA lesion.2,9 Due to the mutagenic activity, 8-oxo-2dG
is capable of imposing deleterious effects on cells including apoptosis induction.9,10 Lin
et al. investigated the generation of 8-oxo-2dG in calf thymus DNA after 2 hours of
exposure to 1 and 10 µM tetrachloro-1,4-benzoquinone in the presence of NADPH and
Cu(II).11 They observed significant production of 8-oxo-2dG in calf thymus DNA treated
with the compound versus untreated calf thymus DNA suggesting that tetrachloro-1,4benzoquinone undergoes redox cycling and produces ROS that are capable of oxidative
DNA lesion induction.11
Assessment of cellular levels of GSH has been frequently used as a marker of
oxidative stress.1 GSH is the most important cellular antioxidant defense nucleophile and
is capable of the detoxification of ROS.12 Failure to maintain the levels of intracellular
GSH upon an oxidative challenge can result in severe consequences for cells including
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loss of function and integrity.12,13 One key aspect of quinone-induced toxicity is the
oxidation of critical intracellular thiols due to redox cycling and induction of oxidative
stress.14,15 GSH depletion has been considered as a marker of oxidative damage induced
by redox-cycling β-lapachone.16 GSH oxidation and depletion during NQO1-mediated
redox cycling of 2-methylmethoxy-1,4-naphthoquinone17 and diaziquone (AZQ)18 in cellfree assays have been reported.
The ability of cells to maintain a proper oxidant/antioxidant balance is a crucial
factor to determine the result of an apoptosis-inducing signal.4 Metabolism of redoxcycling quinones impacts the intracellular redox balance.4 Due to the fact that oxidative
stress is a known trigger of apoptosis, and cytotoxicity of quinone compounds has been
related to the production of free radicals and DNA damage, these compounds should be
potent apoptosis inducers.4
The ability of lavendamycin substrates to induce NQO1-mediated oxidative
stress, oxidative DNA damage and subsequent apoptosis has not been previously
investigated. It is of great importance to examine cytotoxic mechanisms of lavendamycin
analogues to be able to effectively utilize them in combination with other antitumor
agents in cancer therapy. This will facilitate selection of a proper set of antitumor agents
in combination with lavendamycins in chemotherapy and can result in the desired
synergistic antitumor effects of the agents with different mechanisms of action and
toxicities. In addition, combination cancer therapy with antitumor agents with known,
different mechanisms of cytotoxicity could act on various regions of the tumor
microenvironment. This study was designed to investigate the selective induction of
oxidative stress and apoptosis in NQO1-rich cells by good lavendamycin substrates for
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NQO1 versus poor substrates. To determine the induction of oxidative stress in NQO1rich and NQO1-deficient cells by lavendamycin analogues, we examined the generation
of 8-oxo-2dG, an indicator of oxidative DNA damage, and depletion of GSH as relevant
biomarkers of oxidative stress. This is the first study to demonstrate that lavendamycin
antitumor agents cause oxidative stress leading to oxidative DNA damage and apoptosis
in NQO1-rich cancer cells at nM concentrations via NQO1-mediated activation.

5.3

Materials and Methods
5.3.1 8-Oxo-2dG Assay. Oxidative DNA damage was determined by formation

of 8-oxo-2dG according to the protocol developed by Bolin et al.9 Cultured cells (BE and
BE-NQ cells) were harvested by trypsinization. Cells were then transferred into
microcentrifuge tubes (107 cells per tube). Cells were treated with a concentration of 500
nM of compound MB-353 (good substrate) and MB-323 (poor substrate). Treated and
untreated (negative control) cells were incubated at 37 °C under a humidified atmosphere
containing 5% CO2 for 2 hours on a rotator. Next, cells were centrifuged at 1500 rpm for
5 min, supernatant was discarded and the cell pellet was washed twice with 1mL culture
medium and once with 1mL PBS. At this step 300 µL of extraction buffer (Tris-base,
EDTA, DTT, Spermine, Spermidine, protease inhibitors, glycerol and ddH2O) was added
to the cell pellet and cells were sonicated by exposure to five 4-s ultrasound pulses (sonic
disruption on ice for 20 s in 4-s bursts). 30 µL KCl (2.5 M) was then added and rocked
for 30 min in cold room. Next, samples were centrifuged at 14000 x g for 30 min. The
cell pellet was used for the extraction of DNA and subsequent analysis of oxidative DNA
damage. Briefly, the cell pellet was washed with DNA extraction buffer and treated with
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DNAase-free RNAase followed by digestion with proteinase K. The protein fraction was
separated from DNA by three consecutive organic extractions. The DNA was then
precipitated by adding two volumes of ethanol (with respect to the aqueous volume) and
incubated overnight at -20 °C. The DNA was prepared for HPLC analysis by resolving it
into deoxynucleoside components. The amount of 8-oxo-2dG and 2′-deoxyguanosine (2dG) was calculated by comparing the peak area of 8-oxo-2dG and 2-dG obtained from
the enzymatic hydrolysate of the DNA sample to a calibration curve for both
compounds. Levels of 8-oxo-2dG in the samples were expressed relative to the content
of 2-dG, e.g., the molar ratio of 8-oxo-2dG /2-dG (fmol 8-oxo-2dG/nmol of 2-dG).
HPLC system: The mobile phase consisted of 100 mM sodium acetate, pH 5.2, with 5%
methanol. Flow rate was kept at 1 mL/min using a Model 582 Solvent Delivery Module
(ESA, Chelmsford, MA). DNA was analyzed using a reverse phase YMCbasic HPLC
column (4.6 x 150 mm) with a 3-micron particle size (YMC Inc., Wilmington, NC,
USA). 8-Oxo-2dG and 2-dG were detected by a Model 5600A CoulArray Detector
(ESA, Chelmsford, MA) with three model 6210 four channel electrochemical cells.
Potentials were set at 175, 200 and 250 V for 8-oxo-2dG and at 785, 850 and 890 V for
2-dG. Data were recorded, stored and analyzed on a PC Pentium computer using
CoulArray for Windows 32Software (ESA, Chelmsford, MA). Data were expressed as
femtomoles of 8-oxo-2dG per nanomoles of 2-dG.
5.3.2 Reduced Glutathione Assay. The reduced form of glutathione was
determined by a non-recycling system in sample solutions using the ApoGSHTM
Glutathione Colorimetric Detection kit (BioVision, Inc., CA, USA). Cultured cells (BE
and BE-NQ cells) were harvested by trypsinization and diluted with culture medium to
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obtain a cell concentration of 0.5-1 x 106 cells/mL. Cells were then plated in 6-well
plates at a density of 0.5-1 x 106 cells/well and allowed to attach overnight. 500 µL of
culture medium was removed and replaced with 500 µL of medium containing MB-353
(good substrate) and MB-323 (poor substrate) at a concentration of 500 nM. Treated and
untreated (negative control) cells were incubated at 37 °C under a humidified atmosphere
containing 5% CO2 for 2 hours. Next, cells were harvested by trypsinization, centrifuged
at 700 x g for 5 min at 4 °C and supernatant was discarded. The cell pellet was
resuspended in 1 mL culture medium. At this step, cells were incubated for 0, 6, 12 or 24
hours at 37 °C. Cells were then centrifuged at 700 x g for 5 min. The cell pellet was
resuspended in 500 µL ice-cold glutathione buffer, centrifuged at 700 x g for 5 min at 4
°C and supernatant was discarded. Cells were lysed in 80 µL ice-cold glutathione buffer
and incubated on ice for 10 min. 20 µL of 5% sulfosalicylic acid (SSA) was added,
vortexed and centrifuged at 8000 x g for 10 minutes. Then, supernatant was carefully
transferred to fresh microcentrifuge tubes. Reduced form of glutathione was determined
from the supernatant using 5,5'-dithionitrobenzoic acid (DTNB) in the presence of
NADPH without recycling system according to the manufacturer’s instructions.
5.3.3 Detection of Apoptosis. Apoptosis was detected by the enrichment of
mono and oligonucleosomes in the cytoplasm of the apoptotic cells using the cell death
detection ELISA kit (Roche Diagnostics GmbH, Roche Applied Science, Germany).
Cultured cells (BE and BE-NQ cells) were harvested by trypsinization and diluted with
culture medium to obtain a cell concentration of 1 x 105 cells/mL. Cells were then
transferred into microcentrifuge tubes (500 µL/tube = 5 x 104 cells/tube). 500 µL of
culture medium containing compound MB-323 (poor substrate) and MB-353 (good
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substrate) at a concentration of 500 nM were added to the tubes. Treated cells were
incubated at 37 °C under a humidified atmosphere containing 5% CO2 for 2 hours. Next,
cells were centrifuged at 200 x g for 5 min, supernatant was discarded and the cell pellet
was resuspended in 1 mL culture medium. At this step, cells were incubated for 0, 12 or
24 hours at 37 °C. Cells were then centrifuged at 1500 x g for 5 min. The cell pellet was
resuspended with 500 µL incubation buffer per tube (1 x 105 cells/mL). The samples
were incubated for 30 min at 15 to 25 °C to allow the cells to lyse. The lysate was
centrifuged at 20000 x g for 10 min. 400 µL of the supernatant (cytoplasmic fraction)
was carefully removed. The resulting supernatant was prediluted 1:10 with incubation
buffer. The enrichment of mono and oligonucleosomes in the cytoplasmic fraction of the
apoptotic cells was detected by immunoassay according to the manufacturer’s
instructions.

5.4

Statistics

For the 8-oxo-2dG assay, differences between lavendamycin analogue-treated and
untreated cells (negative control) were assessed using single-factor analysis of variance
(one-way ANOVA) and post hoc Tukey’s multiple comparison tests. All results were
reported as mean ± SEM and P ≤ 0.05 was considered significant.
For the reduced glutathione assay, since results were reported as percentage of
negative control (negative control = 100%), differences between lavendamycin analoguetreated cells at different post-exposure incubation periods and untreated cells (negative
control) were assessed using a one-sample t-test adjusted for the number of group means
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tested and directionality of the hypothesis (Bonferroni correction). Results were reported
as mean ± SEM and P ≤ 0.05 (adjusted) was considered significant. To evaluate
differences between lavendamycin analogue-treated cells at different post-exposure
incubation periods, a one-way ANOVA and post hoc Tukey’s multiple comparison test
were used. All results were reported as mean ± SEM and P ≤ 0.05 was considered
significant.
For the apoptosis assay, since the enrichment factor value of the negative control
was considered 1, differences between lavendamycin analogue-treated cells at different
post-exposure incubation periods and untreated cells (negative control) were assessed
using a one-sample t-test adjusted for the number of group means tested and
directionality of the hypothesis (Bonferroni correction). Results were reported as mean ±
SEM and P ≤ 0.05 (adjusted) was considered significant. To evaluate differences
between lavendamycin analogue-treated cells at different post-exposure incubation
periods, a one-way ANOVA and post hoc Tukey’s multiple comparison test were used.
All results were reported as mean ± SEM and P ≤ 0.05 was considered significant.

5.5

Results and Discussion

Many quinone-based antitumor agents including SN,8,19 mitomycin C (MMC),20
β-lapachone,21 AZQ,22-24 EO925-27 and RH128-30 are bioactivated to ctotoxic species by
NQO1. The hydroquinone produced after the two-electron reduction of these agents is
the biologically active form that can cause DNA alkylation and/or oxidative stress.4,21,31
Production of ROS, induction of oxidative stress and DNA damage are important events
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related to quinone reactions and DNA represents the primary biomolecular target for
quinone-based anticancer agents.4,32
5.5.1 Detection of 8-Oxo-2dG Production. Cellular generation of ROS by
redox-cycling quinones can overwhelm cellular antioxidant defense systems, cause
severe oxidative stress and result in the formation of biological markers for oxidative
DNA damage such as 8-oxo-2dG.32-34 The investigation of oxidative stress induction
generally is performed via the measurement of indicators that reflect ROS-induced
damage.2 We observed generation of the biological marker of oxidative DNA damage, 8oxo-2dG, and a significant increase in the molar ratio of 8-oxo-2dG to 2-dG in NQO1rich BE-NQ cells treated by 500 nM MB-353 (good substrate) for 2 hours versus
untreated BE-NQ negative control (Figure 5.1). 8-Oxo-2dG analysis data from cellular
DNA are usually expressed as the ratio of 8-oxo-2dG to the unmodified 2-dG base.2
No significant increase in the corresponding molar ratio was observed in NQO1deficient BE cell line treated with MB-353 compared to untreated BE cells (Figure 5.2).
This suggests that MB-353 as a good substrate for NQO1 can undergo NQO1-mediated
activation in NQO1-rich BE-NQ cells with concomitant production of ROS that can
cause mutagenic oxidative DNA lesions such as 8-oxo-2dG. The cytotoxic mechanisms
of quinones can be attributed to two primary events including redox cycling and
electrophilic alkylation of cellular nucleophiles.4,31 Further studies will be required to
investigate possible DNA strand break formation in BE-NQ cells by MB-353 and the
ability of this compound to alkylate DNA.
Lack of enzymatic activity of NQO1 in BE cells can be considered as the
underlying reason that MB-353 is not activated by NQO1 and cannot induce oxidative
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stress in these cells resulting in subsequent lack of oxidative DNA damage. These
findings suggest an NQO1-mediated selective induction of oxidative DNA damage in
BE-NQ cells by the good substrate MB-353 possibly due to the redox cycling of this
compound.
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Figure 5.1. Effect of MB-353 and MB-323 on the molar ratio of 8-oxo-2dG to 2-dG in
BE-NQ cells after 2-h treatment with the compounds at a concentration of 500 nM.
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Figure 5.1. Effect of MB-353 and MB-323 on the molar ratio of 8-oxo-2dG to 2-dG in
BE-NQ cells after 2-h treatment with the compounds at a concentration of 500 nM. An
HPLC-based analysis was utilized to determine levels of 8-oxo-2dG and 2-dG as
described under Materials and Methods. *Significantly different from negative control
(untreated cells) (P ≤ 0.05). #Significantly different from MB-323 (P ≤ 0.05). Results
are reported as means ± SEM for n = 6 experiments.
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Figure 5.2. Effect of MB-353 and MB-323 on the molar ratio of 8-oxo-2dG to 2-dG in
BE cells after 2-h treatment with the compounds at a concentration of 500 nM.
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Figure 5.2. Effect of MB-353 and MB-323 on the molar ratio of 8-oxo-2dG to 2-dG in
BE cells after 2-h treatment with the compounds at a concentration of 500 nM. An
HPLC-based analysis was utilized to determine levels of 8-oxo-2dG and 2-dG as
described under Materials and Methods. Results are reported as means ± SEM for n = 6
experiments.
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Generation of 8-oxo-2dG by quinone compounds has been reported. Unpublished
data of Gutierrez et al. determined production of 8-oxo-2dG lesions due to redox cycling
of the benzoquinone AZQ.35 Another study demonstrated significant induction of 8-oxo2dG generation in sea urchin embryos exposed to the concentration of MMC as low as 1
µM.36 This study also determined a direct association between MMC-induced toxicity in
the embryos and the related 8-oxo-2dG levels. It has been reported that DNA damage
can induce apoptosis, which is of primary importance to DNA damage-based
chemotherapeutic strategies.37 8-Oxo-2dG has been also considered as a biomarker of
apoptosis.37,38 Although, generation of 8-oxo-2dG is an important biomarker for
estimating oxidative DNA damage,9,10 to date it has never been examined in cancer cells
following exposure to lavendamycin antitumor agents.
No significant increase was observed in the molar ratio of 8-oxo-2dG to 2-dG in
either BE or BE-NQ cells treated by MB-323 (poor substrate) for 2 hours, at the same
concentration as MB-353, versus negative controls (Figures 5.1 and 5.2). This finding
suggests that MB-323 cannot be bioactivated by NQO1 to cytotoxic species capable of
induction of oxidative stress as is indicated by the lack of oxidative DNA damage in
NQO1-rich BE-NQ cells treated by this compound. This is consistent with our
metabolism data for MB-323 that determined this compound as a poor substrate for
NQO1 (See Chapter 2).
Since we observed the production of oxidative DNA damage in BE-NQ cells by
MB-353, depletion of GSH as a biomarker of oxidative stress was also investigated.
5.5.2 Glutathione Depletion. ROS can easily oxidize thiols and deplete
intracellular reduced form of glutathione due to oxidative stress.4 GSH oxidation by ROS
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during redox cycling of quinones is considered a key element of quinone cytotoxicity.15
Our data suggested that reductive bioactivation of MB-353 by NQO1 caused depletion of
GSH in an NQO1-mediated manner in NQO1-rich BE-NQ cells possibly due to redox
cycling of MB-353 (Figure 5.3). Significant reductions in the levels of GSH in these
cells were observed immediately after 2 hours of treatment (zero hour post-exposure time
point) with 500 nM MB-353 implying that GSH depletion is an early event in the induced
oxidative stress process. The levels of GSH in the cells remained significantly low
compared to untreated cells (negative controls) at 6, 12 and up to 24 hours post-exposure
periods (Figure 5.3). The greatest decrease in the GSH levels occurred at the 12 hour
time point suggesting that MB-353 acted as a powerful redox-cycling agent that
exhausted the intracellular GSH pool delaying the GSH replenishment process. One
equivalent of a redox-cycling quinone is capable of producing multiple equivalents of
superoxide anion (O2-.), therefore it can exert its toxicity by exhausting the antioxidant
defense system.39 A trend toward the recovery of the GSH levels in BE-NQ cells was
observed at the 24 hour post-exposure time point, although the level of GSH depletion
was still significant at this time point compared to the negative control (Figure 5.3). No
significant differences between the MB-353-treated BE-NQ cells at different postexposure incubation periods were observed (Figure 5.3). If the cells are not exposed to
the compound in repetitive intervals, the cellular GSH content can recover due to possible
reduction of oxidized form of GSH (GSSG) by glutathione reductase, uptake of intact
glutathione or de novo synthesis of GSH by γ-glutamylcysteine and GSH synthetase.
No GSH depletion was detected in BE cells treated by MB-353 at any of the postexposure time points implying that the reduction in the levels of GSH is an NQO1-related
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selective event for BE-NQ cells compared to BE cells when treated by MB-353 (Figure
5.4). Although the reduction in the levels of GSH in BE cells after MB-353 treatment
was not significant, a trend similar to that for BE-NQ cells was observed exhibiting the
highest reduction in GSH levels at the 12 hour time point.
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Figure 5.3. Effect of MB-353 on the levels of reduced form of glutathione in BE-NQ
cells after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and
24 h post-exposure incubation periods.
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Figure 5.3. Effect of MB-353 on the levels of reduced form of glutathione in BE-NQ
cells after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and
24 h post-exposure incubation periods. Reduced form of glutathione was determined by
a non-recycling system in sample solutions using the glutathione colorimetric detection
kit as described under Materials and Methods. Reduced form of glutathione is expressed
as percentage of negative control (untreated cells). Dashed line represents negative
control. *Significantly different from negative control (P ≤ 0.05). Results are reported
as means ± SEM for n = 3 experiments.
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Figure 5.4. Effect of MB-353 on the levels of reduced form of glutathione in BE cells
after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and 24 h
post-exposure incubation periods.
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Figure 5.4. Effect of MB-353 on the levels of reduced form of glutathione in BE cells
after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and 24 h
post-exposure incubation periods. Reduced form of glutathione was determined by a
non-recycling system in sample solutions using the glutathione colorimetric detection kit
as described under Materials and Methods. Reduced form of glutathione is expressed as
percentage of negative control (untreated cells). Dashed line represents negative control.
Results are reported as means ± SEM for n = 3 experiments.
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Tissue GSH levels decrease in response to chemical compound-induced oxidative
stress.14 The metabolism of redox-cycling quinones in cells and subsequent induction of
oxidative stress cause oxidation of cellular thiol groups that is considered as one
mechanism of quinone-induced toxicity.14 One study determined significant GSH
depletion in primary cultured rat hepatocytes after exposure to 1,4-naphthoquinone.14
This study demonstrated that aloe extract can protect the hepatocytes against 1,4naphthoquinone cytotoxicity via maintenance of cellular thiols.14 GSH oxidation during
NQO1-catalysed redox cycling of AZQ has also been reported.18
Another possible mechanism of GSH depletion after exposure to quinones is due
to alkylation of thiols by these compounds.15,33 The fact that we did not observe
significant GSH depletion in BE cells treated with MB-353 compared to the
corresponding negative control suggested the importance of GSH oxidation rather than
GSH alkylation as the primary mechanism of toxicity of MB-353. Although our results
indicate that MB-353 does not react with GSH significantly, the possibility of some
degree of the alkylation reaction cannot be completely ruled out with our current data.
There is the possibility of low levels of GSH alkylation by MB-353 that can impact the
redox state of the cells. Buffinton et al. determined that menadione-glutathionyl
conjugates can act as NQO1 substrates and undergo redox-cycling reactions.7 Therefore,
the potential generated MB-353-glutathionyl conjugates may act as substrates for NQO1,
be bioactivated by NQO1 and undergo redox cycling with concomitant production of
ROS contributing to the overall induction of oxidative stress in NQO1-rich cells.
To determine whether GSH depletion in the cells was specific to the good
substrate MB-353, we measured the levels of GSH in BE and BE-NQ cells after
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treatment with MB-323. No difference was observed in GSH levels in either cell line
treated with MB-323 (Figures 5.5 and 5.6) suggesting that the observed GSH depletion in
BE-NQ cells was specific to MB-353. The absence of significant depletion of GSH in
BE and BE-NQ cells treated with MB-323 in comparison with negative controls suggests
the lack of GSH alkylation by MB-323 and lack of bioactivation of MB-323 by NQO1,
respectively.
The selective GSH depletion as well as production of 8-oxo-2dG in BE-NQ cells
by MB-353 can result in apoptosis induction in these cells. It has been reported that
several classes of polycyclic aromatic hydrocarbon (PAH) o-quinones can cause cell
death by altering the cellular redox state and causing GSH depletion.33 The effect of
lavendamycin agents on the redox state of cancer cells and the possible involvement of
redox state alteration in the cytotoxicity of these agents have not been previously
examined.
Additional experiments using ROS scavengers and antioxidants will be required
to better determine redox-cycling ability of the lavendamycin analogue MB-353 and the
underlying mechanism of GSH depletion in BE-NQ cells.
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Figure 5.5. Effect of MB-323 on the levels of reduced form of glutathione in BE-NQ
cells after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and
24 h post-exposure incubation periods.
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Figure 5.5. Effect of MB-323 on the levels of reduced form of glutathione in BE-NQ
cells after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and
24 h post-exposure incubation periods. Reduced form of glutathione was determined by
a non-recycling system in sample solutions using the glutathione colorimetric detection
kit as described under Materials and Methods. Reduced form of glutathione is expressed
as percentage of negative control (untreated cells). Dashed line represents negative
control. Results are reported as means ± SEM for n = 3 experiments.
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Figure 5.6. Effect of MB-323 on the levels of reduced form of glutathione in BE cells
after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and 24 h
post-exposure incubation periods.
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Figure 5.6. Effect of MB-323 on the levels of reduced form of glutathione in BE cells
after 2-h treatment with the compound at a concentration of 500 nM at 0, 6, 12 and 24 h
post-exposure incubation periods. Reduced form of glutathione was determined by a
non-recycling system in sample solutions using the glutathione colorimetric detection kit
as described under Materials and Methods. Reduced form of glutathione is expressed as
percentage of negative control (untreated cells). Dashed line represents negative control.
Results are reported as means ± SEM for n = 3 experiments.
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5.5.3 Apoptosis Induction. Oxidative stress has been considered an important
mediator of apoptosis in cells.4 Internucleosomal DNA fragmentation has long been used
as a biochemical index of apoptosis.37 We measured the enrichment of mono and
oligonucleosomes in the cytoplasm of the apoptotic cells to detect apoptosis. BE and BENQ cells incubated with a hypertonic buffer for 2 hours were used as the corresponding
positive controls. Significant induction of apoptosis in positive controls of BE and BENQ cell lines was observed (Figures 5.7 and 5.8). Our data demonstrated that a 2-hour
treatment with MB-353 at a concentration of 500 nM caused significant induction of
apoptosis in BE-NQ cells at 12 and 24 hours post-exposure time points versus the
untreated negative control (Figure 5.7). The greatest induction of apoptosis occurred at
the 12-hour time point (Figure 5.7), which is in accordance with the observed highest
depletion of GSH in these cells at the same time point by MB-353 (Figure 5.3). A trend
toward reduction in apoptosis induction was observed at the 24-hour time point although
it was still significantly higher than the negative control (Figure 5.7). This trend toward
reduced apoptosis induction at the 24-hour time point in the cells can be in part due to the
observed recovery of GSH in the cells at this time point and possible activation of other
repair mechanisms. There was no apoptosis induction immediately after the 2-hour
treatment by MB-353 in BE-NQ cells (Figure 5.7). These findings suggest that induction
of apoptosis in BE-NQ cells by MB-353 compared to the corresponding production of 8oxo-2dG and GSH depletion in these cells (which occur immediately after 2 hours of the
treatment) is a late event that could be in turn the result of the observed oxidative DNA
damage and GSH depletion.
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No significant induction of apoptosis was detected in BE cells treated by MB-353
at any of the post-exposure time points suggesting that bioactivation of MB-353 by
NQO1 results in the induction of apoptosis in BE-NQ cells versus BE cells (Figure 5.8).
Lack of apoptosis induction in the MB-353-treated BE cells is consistent with the lack of
GSH depletion and oxidative DNA damage in these cells after treatment with MB-353.
This suggests that there is a direct association between the presence of the observed
oxidative stress biomarkers and the induction of apoptosis in the MB-353-treated BE-NQ
cells.
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Figure 5.7. Detection of apoptosis in BE-NQ cells after 2-h treatment with MB-353 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods.
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Figure 5.7. Detection of apoptosis in BE-NQ cells after 2-h treatment with MB-353 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods. The
enrichment of mono and oligonucleosomes in the cytoplasm of the apoptotic cells was
detected using the cell death detection ELISA kit as described under Materials and
Methods. The enrichment factor value of the negative control (untreated cells) is
considered 1. Dashed line represents negative control. *Significantly different from
negative control (P ≤ 0.05). Results are reported as means ± SEM for n = 3 experiments.
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Figure 5.8. Detection of apoptosis in BE cells after 2-h treatment with MB-353 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods.
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Figure 5.8. Detection of apoptosis in BE cells after 2-h treatment with MB-353 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods. The
enrichment of mono and oligonucleosomes in the cytoplasm of the apoptotic cells was
detected using the cell death detection ELISA kit as described under Materials and
Methods. The enrichment factor value of the negative control (untreated cells) is
considered 1. Dashed line represents negative control. *Significantly different from
negative control (P ≤ 0.05). Results are reported as means ± SEM for n = 3 experiments.

199

Since two key elements of cytotoxicity of quinones are the production of ROS
and DNA damage, these compounds should be potent inducers of apoptosis.4 The
benzoquinone RH1 has been demonstrated to preferentially cause apoptosis in NQO1rich human breast cancer NQ16 cells compared to parental NQO1-deficient MDA468
cells at lower concentrations.30 Sun et al. demonstrated that SN and MMC induced
significant apoptosis in human colon adenocarcinoma NQO1-rich HT29 cells compared
to NQO1-deficient BE cells implying that bioactivation of these compounds by NQO1
led to apoptosis induction in HT29 cells.19 It has also been shown that NQO1 plays a key
role in apoptosis induction in NQO1-expressing human prostate cancer cells by the
naturally occurring o-naphthoquinone β-lapachone.40 ROS have been implicated in both
death receptor-mediated (extrinsic pathway) and mitochondria-mediated (intrinsic
pathway) apoptosis.41 Further research is required to investigate which apoptotic
pathway is involved in ROS-induced lavendamycin-related cytotoxicity.
MB-323 did not cause apoptosis in BE and BE-NQ cells in comparison with
negative controls at the same concentration as MB-353 (Figures 5.9 and 5.10). Lack of
apoptosis in the BE-NQ cells after exposure to MB-323 is consistent with lack of
detection of biomarkers of oxidative stress in these cells, which suggests that this
compound cannot be bioactivated by NQO1. No observation of an apoptosis event in BE
cells after MB-323 treatment implies that this compound at this concentration cannot
cause enough, direct alkylation of DNA or thiol groups that can result in apoptosis.
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Figure 5.9. Detection of apoptosis in BE-NQ cells after 2-h treatment with MB-323 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods.
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Figure 5.9. Detection of apoptosis in BE-NQ cells after 2-h treatment with MB-323 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods. The
enrichment of mono and oligonucleosomes in the cytoplasm of the apoptotic cells was
detected using the cell death detection ELISA kit as described under Materials and
Methods. The enrichment factor value of the negative control (untreated cells) is
considered 1. Dashed line represents negative control. *Significantly different from
negative control (P ≤ 0.05). Results are reported as means ± SEM for n = 3 experiments.
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Figure 5.10. Detection of apoptosis in BE cells after 2-h treatment with MB-323 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods.
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Figure 5.10. Detection of apoptosis in BE cells after 2-h treatment with MB-323 at a
concentration of 500 nM at 0, 12 and 24 h post-exposure incubation periods. The
enrichment of mono and oligonucleosomes in the cytoplasm of the apoptotic cells was
detected using the cell death detection ELISA kit as described under Materials and
Methods. The enrichment factor value of the negative control (untreated cells) is
considered 1. Dashed line represents negative control. *Significantly different from
negative control (P ≤ 0.05). Results are reported as means ± SEM for n = 3 experiments.
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5.6

Conclusions

The good lavendamycin substrate for NQO1, MB-353, significantly increased the
molar ratio of 8-oxo-2dG to 2-dG in NQO1-rich BE-NQ cells compared to NQO1deficient BE cells. However, no significant increase in the corresponding molar ratio was
observed in BE and BE-NQ cells treated with the poor substrate for NQO1, MB-323.
The acquired data indicate the importance of the role for NQO1 in the bioactivation of
MB-353 and selective induction of oxidative DNA damage in NQO1-rich cells by this
compound. Similarly, MB-353 significantly decreased the levels of GSH only in BE-NQ
cells, while no GSH depletion was observed in either cell line treated with MB-323. This
suggests NQO1-mediated selective depletion of GSH in BE-NQ cells by MB-353 and
that this event is specific to this compound versus MB-323. Therefore, selective
induction of oxidative stress in NOQ1-rich cells was due to NQO1-mediated activation of
MB-353. In addition, this bioactivation of MB-353 by NQO1 resulted in apoptosis
induction in BE-NQ cells versus BE cells, whereas MB-323 did not induce apoptosis in
either cell line. These data are consistent with high and low substrate specificity of MB353 and MB-323 for NQO1, respectively. Overall, our results demonstrated that only the
good lavendamycin substrate, MB-353, caused oxidative stress resulting in oxidative
DNA damage and subsequent apoptosis in NQO1-rich BE-NQ cells at nM concentrations
via NQO1-mediated activation. Future studies are required to further determine other
possible underlying mechanisms of toxicity of lavendamycin analogues including DNA
alkylation and strand break formation. These findings enhance our understanding of the
mechanisms of action of lavendamycin antitumor agents. They can also contribute to the
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development of these compounds as potential anticancer drugs to impact cancer therapy.
A good knowledge of cytotoxic mechanisms of lavendamycin antitumor agents will place
them in a proper combination cancer therapy. Therefore, antitumor agents with known,
various mechanisms of action could act upon different regions of the tumor
microenvironment resulting in an effective antitumor therapy.
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